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AF Amniotic fluid 
AUC Area under the curve 
BMI Body mass index 
BPD Bronchopulmonary dysplasia 
CA12-5 Cancer antigen 12-5 
CI Confidence interval 
CP Cerebral palsy 
CC Clinical chorioamnionitis 
CRP C-reactive protein 
CV Coefficient of variation 
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EONS Early onset neonatal sepsis 
FIRS Fetal inflammatory response syndrome 
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HNE Neutrophil elastase 
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LD Lactate dehydrogenase 
MIAC  Microbial invasion of the amniotic cavity 
MMP Matrix metalloproteinase 
MPO Myeloperoxidase 
NEC Necrotizing enterocolitis 
NICU Neonatal intensive care unit 
9 
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PCR Polymerase chain reaction 
PMN Polymorphonuclear neutrophil 
PPROM Preterm prelabor rupture of membranes 
PPV Positive predictive value 
PVL Periventricular leukomalacia 
RDS Respiratory distress syndrome 
ROC Receiver operating characteristics 
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TIMP Tissue inhibitor of metalloproteinases 





















Chorioamnionitis, the main single cause of preterm delivery, which occurs in 10 to 13% of deliveries 
annually worldwide, can be subdivided into clinical and subclinical forms. The latter is more common and 
includes intra-amniotic infection (IAI), inflammation, and histologic chorioamnionitis (HCA). Diagnosing 
subclinical chorioamnionitis is necessary for optimal timing of delivery.  Amniotic fluid (AF) biomarkers 
allow gathering of information on the inflammatory status of the uterine cavity. 
The aim of the study was to evaluate AF biomarkers in the diagnosis of intra-amniotic infection. 
The study was conducted at the University Hospital of Helsinki, Finland, Department of Obstetrics and 
Gynecology, between March 2012 and October 2015. The study population comprised 155 cases with a 
suspicion of IAI or preterm prelabor rupture of the membranes (PPROM) and 46 controls. Amniocentesis 
was performed in 105 cases between 22+0 and 36+5 weeks of gestation and in 46 controls. AF was 
obtained vaginally from 53 cases. In such AF samples, AF-lactate dehydrogenase (AF-LD) and AF-Glucose 
concentrations were determined. Determination in amniocentesis samples was of AF-LD, AF-Glucose, AF-
matrix metalloproteinase (MMP)-8, AF-cathelicidin, AF-MMP-9, AF-myeloperoxidase, AF-interleukin-6, AF-
neutrophil elastase (HNE), AF-elafin, AF-MMP-2, AF- tissue inhibitor of matrix metalloproteinases -1 (TIMP-
1), AF-MMP-8/TIMP-1 molar ratio, and AF-C-reactive protein (CRP) levels. AF-MMP-8 measurement was by 
an immunoenzymometric assay, AF-LD and AF-Glucose by immunochemiluminometric assays, and others 
by commercial ELISA. Microbiological analyses were based on molecular microbiology and culture 
techniques. An experienced pathologist performed placental histopathologic examination. Data on 
pregnancies came from the hospital database. 
The most optimal cut-off value based on the ROC-curve for AF-LD in vaginally obtained AF against HCA was 
1029 IU/L with a sensitivity of 65% and specificity of 69%. In such samples, glucose concentrations did not 
differ between women with or without HCA. In amniocentesis samples, AF-LD and AF-Glucose correlated 
with HCA and MIAC, and the most optimal cut-off values for both end-points were a respective 429 IU/L 
and 0.7 mmol/L. When AF-LD and AF-Gluc concentrations were adjusted by gestational age at 
amniocentesis, the association disappeared. The concomitant use of AF-LD and AF-Glucose provided no 
additional value. AF-MMP-8, AF-cathelicidin, AF-MMP-9, AF-MPO, AF-IL-6, AF-Elafin, AF-HNE, and AF-TIMP-
1 were associated with MIAC, but AF-MMP-2 and AF-CRP were not. The results were similar also when 
adjusted by gestational age at amniocentesis. Neutrophil-produced biomarkers were associated with IAI. 
MIAC occurred equally often in pregnancies with PPROM and with intact membranes. Infection and 
inflammation were more common at lower gestational ages. 
In conclusion, the accuracies of AF-LD and AF-Glucose were quite poor, meaning that better biomarkers for 
IAI diagnostics are essential. None of the other biomarkers studied out-performed others, and larger 
studies are needed to confirm and further extend our results. However, IAI seemed to be associated with 
neutrophil activation. The usefulness of each biomarker for clinical purposes depends more on local 
circumstances, laboratory method availability, and the clinicians´ familiarity with each biomarker than on 







Intra-amniotic infection or inflammation, one form of chorioamnionitis, is the main etiologic factor in 
preterm delivery (Goldenberg et al. 2008). This association was first described in 1974 (Buhimschi et al. 
2013). Chorioamnionitis may appear in both clinical and subclinical forms. Clinical chorioamnionitis with 
maternal fever as one of the essential signs occurs in 5 to 10% (Edwards 2005) of all preterm deliveries, but 
still represents only the tip of the iceberg. Subclinical chorioamnionitis, occurring more frequently (Wu et 
al. 2009, Galinsky et al. 2013), can be subdivided into histologic chorioamnionitis (HCA), intra-amniotic 
infection (IAI), and intra-amniotic inflammation. IAI is usually defined as intra-amniotic inflammation in the 
presence of microbial invasion of the amniotic cavity (MIAC). However, in the current literature, 
overlapping and incoherence occurs in the definitions and criteria of chorioamnionitis and IAI. 
Chorioamnionitis plays a key role in neonatal morbidity and mortality both in pregnancies complicated by 
preterm prelabor rupture of the membranes (PPROM) and in those with intact fetal membranes (Yoon et 
al. 2001, Kacerovsky et al. 2014, Liu et al. 2014, Roescher et al. 2014, Kim et al. 2015b). IAI causes adverse 
neonatal outcomes similar to those of sterile inflammation (Combs et al. 2014). One of the most significant 
risk factors for chorioamnionitis is PPROM and the following prolonged latency, i.e. time interval between 
the PPROM and the labor (Fishman, Gelber 2012). Although routine prophylactic antibiotics after PPROM 
have reduced the incidence of chorioamnionitis and neonatal infections (Tita, Andrews 2010, Kenyon et al. 
2013), attempts at prevention of adverse outcomes in pregnancies with clinical chorioamnionitis may be 
ineffective (Yoon et al. 2001, Kim et al. 2015b).  
Among the main challenges in modern obstetric practice are early diagnosis of subclinical chorioamnionitis 
and appropriate timing of delivery (weighing the benefits of pregnancy prolongation against risk of fetal 
infection).  
Traditionally, a general inflammation marker in the chorioamnionitis diagnosis has been maternal plasma C-
reactive protein (CRP), although it has proven a poor marker for HCA, MIAC (Stepan et al. 2016), and clinical 
chorioamnionitis (Trochez-Martinez et al. 2007). Due to a lack of exact cut-off levels and a wide range of 
confidence intervals, this marker exhibits very limited clinical usefulness (Buhimschi et al. 2013, Dulay et al. 
2015). No other biomarkers from maternal serum samples are in clinical use.  
A plethora of studies cover AF biomarkers obtained by amniocentesis (AC) in the diagnosis of IAI, but only 
few have undergone clinical validation. Currently in wide use in intra-amniotic infection (IAI) diagnostics are 
AF lactate dehydrogenase (LD) (Garry et al. 1996), glucose (Gluc) (Romero et al. 1990, Greig et al. 1994), 
interleukin-6 , (Romero et al. 1993a, 1993c), and matrix metalloproteinase-8  (Maymon et al. 2000b, Park et 
al. 2013a), but their low accuracy, particularly of AF-LD and AF-Gluc, has limited their clinical use.  
Studies concerning AF biomarkers obtained non-invasively from vaginal samples are few. They have 
revealed an association of AF-LD and AF-Gluc with MIAC, but sample size has been limited (Magloire et al. 
2006b, Buhimschi et al. 2006). Pregnancies with preterm prelabor rupture of membranes (PPROM) are 
frequently associated with oligohydramnion, making AC technically difficult or impossible. In these cases, 
AF sampling vaginally from leaking AF would be of great value.  
Taking into consideration the fact that in pregnancies with preterm labor and intact fetal membranes IAI 
and subclinical chorioamnionitis are frequent (Romero et al. 2014c), we wanted to explore the value of 
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traditional and novel biomarkers in the diagnosis of these entities both in pregnancies with PPROM and 
with intact fetal membranes. The inconsistent and limited results from the biomarkers obtained vaginally in 


































Preterm delivery is defined by the World Health Organization (WHO) as delivery at less than 37 weeks of 
gestation (Goldenberg et al. 2008, Harrison, Goldenberg 2016), without any limit for neonatal weight. The 
lower limit for delivery varies between countries, but in Finland it is set at 22+0 weeks of gestation or 
weight of the neonate over 500 g (THL 2016). 
Worldwide, the rate of preterm birth is about 11% (Harrison, Goldenberg 2016), and 15 million preterm 
births occur annually (Galinsky et al. 2013). The rate has stayed almost stable during recent decades 
(Norman, Shennan 2013), or has even risen (Galinsky et al. 2013). In Finland, the rate of preterm birth is 
5.3% (THL 2016), similar to other European countries’ (Cappelletti et al. 2016), and it has remained quite 
stable over 15 years (THL 2016).  
Preterm birth can be classified as spontaneous or induced preterm birth. The former can be further 
subdivided into preterm birth with intact membranes, and preterm birth starting with preterm prelabor 
rupture of the membranes (PPROM). Preterm delivery starting with PPROM comprises 30 to 40% of all 
preterm deliveries, while the number of term deliveries with PPROM is only 2 to 3.5% (Henderson et al. 
2012, Erdemir et al. 2013). Most PPROM cases occur between 34 and 37 weeks of pregnancy (Kacerovsky 
et al. 2014).  
Infection or inflammation is the main single cause of preterm birth, and is responsible for approximately 
25% of all preterm births (Goldenberg et al. 2008, Cappelletti et al. 2016).  Infections can be subdivided into 
intrauterine and extrauterine infections, the latter including malaria, pyelonephritis, pneumonia, and 
periodontitis (Parthiban, Mahendra 2015). Moreover, chronic inflammatory conditions in the mother, like 
obesity, autoimmune diseases such as systemic lupus erythematosus, multiple sclerosis, and type 1 
diabetes (Cappelletti et al. 2016), are associated with increased risk for preterm birth. Furthermore, an 
altered maternal microbiome in the oral cavity or placenta can also cause an increased risk for preterm 
birth (Jain, Gyamfi-Bannerman 2016, Vinturache et al. 2016). Microbe-associated infection is not a 
necessary cause of increased risk for preterm birth, because sterile intra-amniotic inflammation also 
elevates the risk for preterm labor at <34 weeks of gestation (Romero et al. 2014b). The most important 
risk factor for preterm birth is, however, a maternal history of preterm birth, especially in the early weeks 
of gestation (Vinturache et al. 2016). 
Preterm birth is the leading cause of neonatal mortality (Slattery, Morrison 2002), and it causes 
approximately 35% of neonatal deaths during the first four weeks of life (Norman, Shennan 2013, Harrison, 
Goldenberg 2016), and altogether 75% of total perinatal mortality (Slattery, Morrison 2002, Goldenberg et 
al. 2008). Improvement in neonatal outcome has occurred since antenatal corticosteroids and magnesium 
neuroprophylaxis have been incorporated into clinical management. Antenatal corticosteroid 
administration between 24 and 34 weeks of gestation in the setting of threatening preterm labor has 
reduced the risk for respiratory distress syndrome (RDS) for over 20 years in high-income countries. In low-
income countries, accessibility of antenatal corticosteroids is less frequent (Harrison, Goldenberg 2016). 
Administration of magnesium sulfate to the mother with threatening preterm delivery <32 weeks of 
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gestation has shown beneficial effects on the newborn´s neurodevelopmental outcome, mainly by reducing 
the incidence of cerebral palsy (CP) (Kamyar et al. 2016). The number needed to treat to prevent one case 
of CP is 63 (95% CI 43-155) (Doyle et al. 2009).  However, in one recent study, magnesium neuroprophylaxis 
had no favorable effect on neonatal outcome in neonates born at <32 weeks of gestation in the setting of 
chorioamnionitis (Kamyar et al. 2016).  
 
Economic consequences of preterm birth 
 
One approximation of annual costs of prematurity in the USA, in 2007, was 26.2 billion dollars (Behrman, 
Butler 2007). Costs of prematurity are not only due to hospitalization in the neonatal period, but also due 
to a lifelong need of special help for those with handicaps, along with increased need for healthcare and 
social services (Saigal, Doyle 2008, Platt 2014).  In PPROM pregnancies, between 34 and 37 weeks of 
gestation, induction of labor costs more than does expectant management (Vijgen et al. 2014). Delayed 
labor from 34 weeks to 35 weeks can achieve a 42% decrease in neonatal costs. Moreover, delay of one 
more week yields a 38% extra decrease in neonatal costs (Loftin et al. 2010). The incremental costs of 
prematurity over those of full-term infants from birth to age 18 years have been approximated to be for 
preterm (<37 weeks of gestation) infants 1.5 times as high, for very preterm (28-32 weeks) infants 2.5 times 





Chorioamnionitis refers to the inflammatory changes of the chorion-plate, amniotic membranes, or both 
(Higgins et al. 2016). Inflammation may be subsequent to microbial invasion of the amniotic cavity (MIAC), 
or it may occur without proven microbiologic etiology (Romero et al. 2014c). Microbes leading to 
chorioamnionitis, according to current knowledge, consist of bacteria, viruses, and yeasts (Ramos Bde et al. 
2015). Those microbes may reach the amniotic cavity by the following routes: 1) ascent from the vagina, 2) 
hematogenous spread, 3) iatrogenic spread during an invasive procedure, such as amniocentesis (AC) or 






Figure 1. Routes of microbes to reach the amniotic cavity; from. L. Rahkonen thesis 2010 with the kind 
permission of the author. 
 
Intra-uterine infection may exist in amniotic fluid (AF) (amnionitis), in the fetal membranes 
(chorioamnionitis), between maternal and fetal tissues (choriodeciduitis), in the placenta, in the umbilical 
cord (funisitis), or in the fetus (Figure 2) (Goldenberg et al. 2000).  






Figure 2. Sites of infection in the uterus. At bottom, from 
L. Rahkonen thesis 2010, reprinted with permission of 
the author. At top, drawn by the author. 
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The mechanism behind infection and preterm labor consists of microbes releasing endotoxins and 
exotoxins which are recognized by a maternal host response, i.e. Toll-like receptors existing on the surface 
of leukocytes, and epithelial and trophoblast cells. This leads to production of pro-inflammatory cytokines, 
such as interleukin-6 (IL-6), and chemokines in the decidua and fetal membranes. Cytokines then activate 
an inflammatory cascade, in which prostaglandins are produced, and acute-phase reactants like C-reactive 
protein (CRP) are released into the circulation, and neutrophils are activated.  Neutrophils migrating to the 
infectious site release proteases such as matrix metalloproteinases (MMPs) and their regulators, like tissue 
inhibitors of metalloproteinase -1 (TIMP-1) (Alfakry et al. 2016). Prostaglandins stimulate uterine 
contractions, and metalloproteinases stimulate collagen degradation, leading to cervical softening and 
preterm labor or rupture of the amniotic membranes (Galinsky et al. 2013, Fox, Eichelberger 2015) (Figure 
3).  
The mechanism behind sterile inflammation is, instead, considered to involve stimuli leading to release of 
endogenous molecules, called alarmins, which evoke a host response through Toll-like receptors, leading to 
an inflammatory process and causing sterile HCA (Kacerovsky et al. 2014, Romero et al. 2014c). 
 
 
Figure 3. Inflammation cascade. Modified from Alfakry 2016, with the kind permission of SAGE Publishing. 
MPO, myeloperoxidase; H2O2-chloride, hypochlorus-acid; MMP-8, matrix metalloproteinase-8, TIMP-1, tissue 
inhibitor of metalloproteinases-1; MMP-9, matrix metalloproteinase-9; PPROM, preterm prelabor rupture of the 
membranes. 
 
Several mechanical and functional barriers protect the amniotic cavity from an external microbial load (King 
et al. 2007b). This is crucial in maintaining pregnancy continuation. The placenta and amniotic membranes 
form a mechanical barrier (Tita, Andrews 2010) including syncytiotrophoblasts surrounding the villi (Redline 
2004). Amnion epithelium and trophoblasts also act as a functional barrier by producing antimicrobial 
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peptides (King et al. 2007a, 2007b, Stock et al. 2007). The mucus plug in the closed cervical canal is also 
both an anatomical and functional barrier to microbial invasion from the vagina (Kim et al. 2015a). 
Functional barriers also include vaginal lactobacilli flora affecting the virulence of micro-organisms (Tita, 
Andrews 2010), and cervical epithelial cells´ microbicidal products (cathelicidin, calgranulins, and defensins 
like elafin) participating in blocking ascending infections (Hein et al. 2002, Stock et al. 2009, Buhimschi et al. 
2013, Frew et al. 2014), and endometrial glandular cells producing antibacterial proteins (Redline 2004).  
In the chorioamniotic unit, neutrophils and decidua originate from maternal side, but the villus tree and 
chorioamniotic membranes from the fetal side (Kim et al. 2015a). In a normal, non-infectious situation 
neutrophils are absent from the chorioamniotic membranes (Kim et al. 2015a), but the number of maternal 
neutrophils increases shortly before upcoming labor in the decidua and myometrium (Keski-Nisula et al. 
2000, 2003, Gomez-Lopez et al. 2014). Inflammation in such tissues is physiological phenomena occurring 
during normal labor.  
 
Definition and classification 
 
Although the term “chorioamnionitis” in clinical practice often refers to several signs and symptoms, for 
example to uterine tenderness, infectious discharge from the uterine cervix, or increased infection 
parameters along with maternal fever, chorioamnionitis can be subdivided into two distinctive subgroups: 
clinical and subclinical. The latter consists of HCA and intra-amniotic inflammation with or without 
microbiologic etiology (Figure 4). 
 
Figure 4. Schematic diagram of chorioamnionitis types. Subclinical chorioamnionitis can be subdivided into 
histologic chorioamnionitis (HCA), intra-amniotic infection (IAI), and intra-amniotic inflammation. IAI means 







Clinical chorioamnionitis has been traditionally defined by Gibbs criteria since the 1970s (Gibbs 1977, Sung 
et al. 2016). It includes maternal fever ≥ 38 ºC with at least one or two of the following criteria: uterine 
tenderness, maternal or fetal tachycardia, foul-smelling or infectious discharge from the uterine cervix, or 
total maternal white blood cell (WBC) count > 20 x 109/L (Fishman, Gelber 2012, Romero et al. 2015).  
Intra-amniotic infection and inflammation 
 
Intra-amniotic infection (IAI) is defined as elevated concentration of inflammatory markers, such as IL-6, 
and matrix metalloproteinase -8 (MMP-8) in AF in the presence of MIAC. The microbial colonization, per se, 
is not considered consistent with infection; an inflammatory component is necessary (Combs et al. 2014). 
Intra-amniotic inflammation in the absence of MIAC results from activation of endogenous mediators which 
evoke a host response and lead to progression of an inflammatory process. 
Histologic chorioamnionitis 
 
The placenta consists of three parts: the chorionic plate, the chorioamniotic membranes, and the umbilical 
cord. The term HCA refers to inflammatory changes, i.e. neutrophil infiltration, mainly polymorphonuclear 
leukocytes, in any of these parts.   
HCA can be subdivided according to inflammatory changes in the villus tree (villitis), vessels (vasculitis), or 
umbilical cord (funisitis). Funisitis is defined as a neutrophil infiltration into the vessel walls of the umbilical 
cord or into Wharton´s jelly (Park et al. 2016). It is considered a more severe stage of HCA, since it reflects 
the spread of inflammation to the umbilical cord, and is the fetal counterpart to the maternal infection 
(Tita, Andrews 2010).  
HCA covers two subtypes of chorioamnionitis: with MIAC (infectious) and without MIAC (sterile) (Romero et 
al. 2014c). Inflammatory changes in the latter are thought to be caused by the host immune response 
(Redline 2004) or by meconium (Menon et al. 2010). Manifestation of the infection depends on the 
virulence of microbes in the chorioamniotic space: subsequent clinical chorioamnionitis follows infection by 
highly virulent microbes, whereas subclinical HCA usually occurs in the presence of low virulence microbes 
(Galinsky et al. 2013). 
 
 
Risk factors for chorioamnionitis 
 
PPROM and the latency time between membrane rupture and delivery are among the most important risk 





Table 1. Risk factors for chorioamnionitis. 
    
Nulliparity Digital examinations during delivery 
Prolonged PPROM Meconium-stained amniotic fluid 
Bacterial vaginosis Prolonged duration of delivery 
Sexually transmitted genital infections Intrauterine monitoring (CTG, IUP) 
Alcohol- or drug abuse Epidural use 
Tobacco smoking 
GBS colonization in maternal vagina or 
     perineum 
Immunosuppression 
African-American ethnicity 
Altered placental or vaginal microbiome 
Based on data from Tita 2010, Fishman 2012, Johnson 2014, Prince 2014 
CTG, cardiotocography; GBS, Group B Streptococcus; IUP, intrauterine pressure;  




Women with preterm labor have a diminished amount of protective Lactobacillus spp. in their vaginal flora 
and a predominance of Gardnerella or Ureaplasma species (DiGiulio et al. 2015). Moreover, pre-existing 
viral load may induce inflammation or preterm birth (Ramos Bde et al. 2015). 
Formerly, the genital tract beyond the cervix was presumed to be sterile, but the placenta harbors its own 
microbiome, which is more related to an oral microbiome than to a vaginal microbiome (Aagaard et al. 
2014, Mysorekar, Cao 2014, Prince et al. 2014, Fox, Eichelberger 2015, Prince et al. 2016). The placental 
microbiome differs between women with preterm labor or a history of antenatal infection and those 
achieving full-term pregnancies (Prince et al. 2016) (Table 2). The most common bacterium of the placenta 
is E.coli (Aagaard et al. 2014). Placental microbes are usually not pathogenic. However, the altered immune 
system during pregnancy may lead to hematogenous colonization, changes in the community of placental 
microbes, and thereafter to dysbiosis, which can evoke an inflammatory response leading to preterm labor 










Table 2. Maternal microbiome by pregnancy outcome. 
Preterm labor,  
intact membranes 
Preterm labor,  
PPROM 
Term labor  
without chorioamnionitis 
Term labor with 
chorioamnionitis 








Bergeyella spp.       NA Actinobacteria       NA 
Streptococcus spp. Bacteroidetes 
Proteobacteria 
Fusobacterium 
Amniotic fluid: Amniotic fluid: Amniotic fluid: Amniotic fluid: 
Ureaplasma spp. Ureaplasma spp. Ureaplasma spp. Ureaplasma spp. 
Mycoplasma spp. Mycoplasma spp. Mycoplasma Mycoplasma 
Fusobacterium Fusobacterium Coagulase negative Staphylococcus Fusobacterium 
Sneathia Sneathia Streptococcus agalactiae Sneathia 
Bacteroides Bacteroides Lactobacillus spp. Bacteroides 
Prevotella Prevotella Acinetobacter spp. 
Leptotrichia Leptotrichia Lactobacillus spp. 
Peptostreptococcus Enterococcus Enterococcus 
Escherichia coli Hemophilus Gardnerella 
Gardnerella Streptococcus Streptococcus 
Bacillus Staphylococcus Escherichia coli 
Placenta: Placenta: Placenta: Placenta: 
Ureaplasma spp.↑ Ureaplasma spp.↑ Enterobacter Enterobacter 
Acinetobacter↓ Acinetobacter↓ Acinetobacter Acinetobacter 
E.coli E.coli E.coli E.coli 
Enterobacter Enterobacter Lactobacillus spp. Lactobacillus spp. 
Fusobacterium ↑ Fusobacterium ↑ 
Lactobacillus crispatus ↓ Lactobacillus crispatus ↓ 
Vagina: Vagina: 
Lactobacillus crispatus   Lactobacillus spp.   
↑ increased microbe level compared to that of term pregnancy without chorioamnionitis 
↓decreased microbe level compared to that of term pregnancy without chorioamnionitis 
NA, not available 









Clinical chorioamnionitis occurs in 1 to 4% of all pregnancies in developed countries (Johnson et al. 2014). 
Data of developing countries are lacking. The rate is higher in preterm pregnancies (5-15%) than in term 
pregnancies (1-2%) (Edwards 2005). Chorioamnionitis cannot develop until the amnion and chorion are 
fused (on average 11 weeks of gestation), and it occurs rarely before fusion of the placental membranes 
with the uterine cavity (on average at 19 weeks of gestation) (Redline 2012). In pregnancies complicated 
with PPROM clinical chorioamnionitis occurs in up to 26% (van de Laar et al. 2009). Of women with clinical 
chorioamnionitis, 62% have HCA, and 60% have funisitis (Tita, Andrews 2010). Subclinical chorioamnionitis 
is more common than clinical chorioamnionitis, which occurs in only 18% of pregnancies with intra-
amniotic inflammation (Buhimschi et al. 2013).  
IAI (57% vs 42%) and intra-amniotic inflammation (29% vs 21%) occur more frequently in PPROM 
pregnancies than in preterm pregnancies with intact membranes (Park et al. 2013d) (Table 3).  
 
Table 3. The rate of chorioamnionitis 
Study n Setting 
Term/ 
Preterm Outcome Prevalence % 
















Romero et al 2015 59 PPROM Preterm 
Sterile inflammation 
IAI 
HCA among those without 
   inflammation 






Romero et al 2014 231 
Intact membranes 






HCA without inflammation 
HCA among those with  
    inflammation 







Kim et al 2015  Review 
Term and 
preterm 
MIAC with CC at term 
MIAC with preterm labor and 
     intact membrans 
MIAC with PPROM without 














Erdemir et al 2013 43 PPROM and intact 
membranes 













Kim SM et al 2014 412 Intact membranes 24-35 GW 
HCA 
Inflammation 
HCA among those with  
    inflammation 
HCA without inflammation 







Roberts et al 2012 195 Intact membranes; low-risk women Term HCA 34 
Ovalle et al 1998 71 PPROM 24-34 GW HCA 
HCA with MIAC 
58 
51 




Seong et al 2008 884 Intact membranes Term MIAC not in labor 
MIAC in active labor 
1 
13 
Cobo et al 2012 66 PPROM 22-33+6 GW MIAC 20 
Romero et al 2014 142 Intact membranes 20-35 GW 
MIAC By PCR/ESI-MS 
MIAC by culture 
HCA in culture+, PCR+ 
HCA in PCR+ 






GW, gestational weeks; HCA, histologic chorioamnionitis; MIAC, microbial invasion of the amniotic cavity; IAI, intra-amniotic 
infection; CC, clinical chorioamnionitis; PPROM, preterm prelabor rupture of the membranes; PCR, polymerase chain 




The prevalence of MIAC in preterm labor or in PPROM varies greatly among studies. The discovery of 
bacteria in AF was first reported in 1927 (DiGiulio 2012).  In PPROM cases, MIAC occurs in 20 to 50%, while 
in preterm labor with intact membranes, MIAC is detectable in 6 to 20%  (Yoon et al. 1998, Ovalle et al. 
2006, DiGiulio et al. 2010, Lisonkova et al. 2014, Romero et al. 2014c). The occurrence of preterm 
contractions in the latter situation increases the prevalence of MIAC to as high as 50% (Genc, Ford 2010). 
MIAC also occurs in 7 to 22% of women having a short cervix (Gomez et al. 2005, Hassan et al. 2006, 
Kusanovic et al. 2007).  Furthermore, bacteria and viruses may be detectable in AF also in uneventful 
pregnancies (Ramos Bde et al. 2015). Microbes are reported in AF in only about 1% of women at term 
pregnancy before parturition without any signs of infection (Seong et al. 2008).  
The rate of polymicrobial MIAC cases shows a wide variability between 9 and 67% (Tita, Andrews 2010, 
DiGiulio 2012, Romero et al. 2014a, Kim et al. 2015a). The most common microbe found in AF is 
Ureaplasma urealyticum /parvum, a typical microbe of the lower genital tract (Combs et al. 2014, Murtha, 
Edwards 2014). The spectrum of microbes differs between women with preterm labor with intact 
membranes and PPROM (DiGiulio 2012). 
The role of viruses in the field of IAI is not yet fully understood, though their presence in the AF is more 
frequent than previously thought. (Baschat et al. 2003). Viruses isolated from AF include parvovirus B19, 
human herpesvirus-6, cytomegalovirus, Epstein-Barr virus, enterovirus, adenovirus, syncytial virus, and zika 
virus (Ramos Bde et al. 2015, Calvet et al. 2016), though no proven association exists between AF viruses 
and adverse outcomes or pregnancy loss (Miller et al. 2009, Bopegamage et al. 2013, Ramos Bde et al. 
2015). However, adenovirus has been detected in 40% of preterm placentas, and HCA also occurs more 
frequently in placentas containing adenovirus (Tsekoura et al. 2010).  
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Candida albicans is the most common of the Candida species detected from AF (DiGiulio 2012). The rate of 
Candida in AF is quite low, but robust neonatal infections have been reported, often related to early 
gestational age (DiGiulio 2012).  
Archaea also have the pathogenic potential to promote MIAC (DiGiulio 2012), but with no IAI cases 
reported. Protozoa, like Toxoplasma gondii and Trypanosoma cruzi, have also been detected in the AF 
(DiGiulio 2012), but studies concerning Plasmodium malariae in AF are lacking, although placental malaria 
is, however, quite common (DiGiulio 2012). No IAI resulting from these zoonoses has been reported. 
The lower the gestational age, the higher the frequency of HCA (Lahra, Jeffery 2004). Variation in HCA 
frequency is great from 94% at a lower gestational age to 5% at full term (Horvath et al. 2014, Kim et al. 
2015a). However, the absolute number of HCA cases in term pregnancies is high (Roberts et al. 2012). 
Racial variability has also been reported in the frequency of HCA (Nadeau et al. 2016). The rate of HCA 
varies markedly, from 24 to 80% with PPROM (Menon et al. 2010, Lee et al. 2013a, Xie et al. 2015), and up 
to 88% in women with intact membranes and preterm labor (Greig et al. 1994, Menon et al. 2010). In term 
pregnancies, HCA is mainly non-infectious, instead is just an inflammatory phenomenon (Roberts et al. 
2012). Labor itself is an inflammatory process (Keski-Nisula et al. 2000), which is evident in term 
pregnancies as a higher rate of HCA in women in labor than prior to labor (Keski-Nisula et al. 2000, Kim et 
al. 2015a). Sterile HCA is more common than MIAC-related HCA in preterm pregnancies with intact 
membranes, and it occurs more frequently at a lower gestational age, as does microbe-related HCA 
(Romero et al. 2014c). In PPROM pregnancies, the rate of sterile HCA has been reported at 44% (75/167 
cases) (Vajrychova 2016).  
Funisitis occurring in 60% of pregnancies with HCA (Tita, Andrews 2010) is present in about 1% of term 
pregnancies with intact membranes without clinical signs of chorioamnionitis and in 7% with prelabor 
rupture of the membranes before parturition (Lee et al. 2006). During labor, funisitis occurs in 3% if 
membranes are intact and in 4% if membranes are ruptured (Lee et al. 2006). In preterm pregnancies, 
funisitis occurs in 31% in PPROM pregnancies with HCA, but in pregnancies with intact membranes it does 






The use of maternal fever as an obligatory criterion for the diagnosis of clinical chorioamnionitis originally 
described by Gibbs in 1977 is puzzling. Recent evidence show that the removal of fever as an essential 
criterion for chorioamnionitis enhances the sensitivity of prediction of neonatal sepsis in all preterm 
pregnancies between 24 and 34 weeks of gestation (Sung et al. 2016). The symptoms and signs of 
chorioamnionitis can also result from physiological reactions to delivery, making, however, the clinical 
criteria of chorioamnionitis neither sensitive nor specific. In the diagnosis of IAI, it is unacceptable to use 
such method with a maximal accuracy of only 57% (Romero et al. 2016b).  
Maternal fever as an isolated finding occurs in about 15% of term deliveries (Evers et al. 2012). Other 
common conditions causing fever during labor include epidural anesthesia, dehydration, extrauterine 
infections, hyperthyreosis, and prostaglandins used for labor induction (Greenwell et al. 2012, Curtin et al. 
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2015, Higgins et al. 2016, Sultan et al. 2016). After clinical protocol to administrate antibiotic prophylaxis to 
all women positive for Group B Streptococcus and to women with PPROM, the role of fever as a sign of 
chorioamnionitis in the presence of other symptoms of chorioamnionitis has become disputed (Sung et al. 
2016). However, intrapartum fever, per se, can cause changes in fetal immune response (Mazaki-Tovi, 
Vaisbuch 2016), and is recommended to commence clinical interventions (Avila et al. 2015).  
The role of maternal CRP in the diagnosis of chorioamnionitis is controversial.  Maternal plasma CRP value 
≥20 mg/L and WBC value ≥15 x 109/L have served as diagnostic markers for chorioamnionitis (Keski-Nisula 
et al. 1995), but 10 to 12 hours pass before the inflammatory response is evident in CRP (Hofer et al. 2012). 
Furthermore, maternal CRP and WBC may be elevated during normal labor (Keski-Nisula et al. 1995), and 
CRP increases also in uneventful pregnancy when compared to the non-pregnant stage (Anderson et al. 
2013). Close to delivery, the levels of CRP and WBC may show a wide range of variability, making a 
prediction of chorioamnionitis based on those values unreliable (Le Ray et al. 2015). Furthermore, CRP and 
WBC have shown poor diagnostic performance for HCA (Sereepapong et al. 2001), for clinical 
chorioamnionitis (van de Laar et al. 2009), or at least their clinical value is limited (Le Ray et al. 2015). In 
one study, however, CRP was a better predictor for HCA in cases without IAI than was AF MMP-9 or IL-6 
(Oh et al. 2011).  
Studies of CRP and chorioamnionitis in pregnancies with intact membranes are few (Cammu et al. 1989, 
Park et al. 2013b). In one such study, CRP in preterm pregnancies was associated with IAI (Park et al. 
2013c). In systematic reviews of PPROM pregnancies, no clear consensus exists as to use of CRP in diagnosis 
of chorioamnionitis (Trochez-Martinez et al. 2007, van de Laar et al. 2009).  
Nor is fetal cardiotocography a particularly sensitive tool in chorioamnionitis diagnostics, since only 16 to 
38% of neonates having an infection had tachycardia during the delivery (Evers et al. 2012). Studies 
concerning fetal tachycardia prior to delivery in cases of chorioamnionitis are lacking, but one case report 
concerns identified tachycardia (Kelly et al. 2014).  
 
Intra-amniotic infection / inflammation 
 
Intra-amniotic infection / inflammation can be diagnosed through AF biomarkers obtained by AC or 





Amniocentesis (AC) has been performed since 1877 (Woo 2006). It has been in use mostly for genetic 
karyotyping since 1956 (Fuchs, Riis 1956), and has served, though less frequently, for diagnosis of intra-
amniotic infection since 1979 (Garite et al. 1979). Other common indications for this invasive procedure 
include testing for fetal lung maturation or chronic fetal hypoxia (erythropoietin).  
Neonatal outcome was indeed improved when AC was incorporated into the protocol of management of 


































neonatal outcome in groups 
AC vs No AC. Also twins 
included. 
 
Composite neonatal morbidity was 
increased in No-AC group OR 2.94 
(95%CI 1.68-5.15);  
No difference in PVL, IVH, death, 
NEC, ROP. 
Neonatal sepsis in No-AC group 
similar to AC group with positive 
culture. 






Intact membranes, threatened 
preterm labor.  
Association of biomarkers / 
culture with adverse neonatal 
outcome, adjusted for 
gestational age. 
 
AF infection and/or elevated TNF-α 
was  
associated with RDS aOR 1.7;  
Gr 3-4 IVH aOR 2.2; 
NEC aOR 1.8; 
Multiple organ dysfunction aOR 3.0 










Intact membranes,  
threatened preterm labor.  
Comparison of neonatal 
outcome in AC vs No AC 
groups. 
EONS n=5 vs n=13, p<0.03 
Short-term outcome n=8 vs n=20, 
p<0.05 
Long-term outcome n=7 vs n=21, 
p<0.01 









185 women with a pregnancy 
complicated with PPROM. AC 
for 123 women. Neonatal cord 
blood biomarkers and short 
term neonatal outcome was 
compared in the groups: AC+, 
proven infection, AC+, no 
infection, and no AC. 
Antenatal exposion to IAI elevates 
risk for adverse neonatal outcome 
OR 3.0 (95% CI 1.15-7.59); higher 
gestational age and AC reduced risk 
for adverse neonatal outcome OR 
0.61 (95%CI 0.52-0.7) and OR 0.37 
(95% CI 0.14-0.95), respectively.   
AC, amniocentesis; PPROM, preterm prelabor rupture of the membranes; OR, Odds ratio; aOR adjusted Odds Ratio; GW, gestational 
weeks; IL-6, interleukin-6; LD, lactate dehydrogenase; TNF-α, Tumor necrosis factor-α; RDS, respiratory distress syndrome; IVH, 
intraventricular hemorrhage; PVL, periventricular leucomalacia; ROP, retinopathy of prematurity; NEC, necrotizing enterocolitis; 
EONS, early-onset neonatal sepsis 
Short-term outcome, presence of variables: IVH gradus 3-4, periventricular leucomalacia, hydrocephalus and brain atrophy. 




AC is usually performed transabdominally with ultrasound guidance and an aseptic technique. It is an 
invasive but a relatively safe procedure (Yeast et al. 1984, Gordon et al. 2002, Akolekar et al. 2015). The 
most common complications afterwards are miscarriage before 24 weeks of gestation (0.4-0.81%) 
(Enzensberger et al. 2012, Akolekar et al. 2015), or rupture of the amniotic membrane (0.9-4.2%) (Zalud, 
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Janas 2008, Lee et al. 2013b), as well as intra-amniotic infection (0.1-0.4%), and septic shock as a rare 
consequence (0.03-0.19%)  (Wurster et al. 1982). The risk for any complication following AC that requires 
delivery is 0.7% (Stark et al. 2000). Notably, intra-amniotic inflammation / infection is the only variable 
associated with membrane rupture after AC (Lee et al. 2013b).  
 
Amniotic fluid biomarkers: 
 
AF WBC count, which is increased in inflammatory conditions, has for many years been the gold standard 
indicating AF inflammation (Buhimschi et al. 2013, Park et al. 2013a). WBC lysis in the presence of bacteria 
may yield an artificially lower result, and contamination with blood may yield false positive results. For the 
role of selected biomarkers in normal pregnancies as well as their sites of production, see Table 5. 
Several other biomarkers studied in the diagnosis of IAI are not in clinical use. One of those is CA12-5, 
which has shown an association with intra-amniotic inflammation and preterm labor (Seong 2016). During 
recent years, biomarkers related to oxidative stress and inflammation as well as AF proteomics have been 
under investigation (Cobo et al. 2013, Chafer-Pericas et al. 2015). 
 
Increased concentration of AF-LD reflects inflammation or neutrophil activation in the amniotic cavity. 
Lactate dehydrogenase (LD) is an enzyme which catalyzes the reversible conversation of lactate to pyruvate 
at the end of the glycolytic pathway. Leukocytes and macrophages at the site of inflammation are the major 
source of aerobic glycolysis and therefore of LD (Magloire et al. 2006a).  In body fluids, for example in 
ascites fluid, LD acts as an inflammation marker (el-Touny et al. 1989, Kidokoro et al. 2006). The accuracies 
of AF-LD and other biomarkers for inflammation and infection in the setting of preterm labor with and 
without PPROM are presented in Table 6. One possible source of bias concerning AF-LD is the blood in AF 














Table 5. Characteristics of amniotic fluid inflammatory biomarkers investigated. 
Biomarker Site of production 







LD Neutrophils Catalyzes oxidation of  lactate to puryvate. Raises ? 
Garry et al 1996, 
Kidokoro et al 2006, 
Miura et al 2011 
Glucose Maternal liver  and muscles 
Reflects maternal serum 
glucose concentration. Reduces ? 
Hussey et al 1998, 
Rinala et al 2009 
MMP-8 Neutrophils   Degrades extracellular matrix at parturition. Raises No effect 
Maymon et al 2000, 
Romero et al 2014 
Cathelicidin Neutrophils and epithelial cells 
Modulates adaptive immunity and 
takes part in innate immunity. Raises ? 
Tambor et al 2012 
MMP-2 Fetal membranes 
Cleave denatured collagen and 
basement membrane 
components. Major modulator of 
fetal membrane integrity 
throughout gestation. 
Reduces* Reduces 
Maymon et al 2000, 
Locksmith et al 2001, 
Vincent et al 2015 
MMP-9 Fetal membranes 
Cleave denatured collagen and 
basement membrane 
components. Modulator of fetal 
membrane strength. Plays an 
important role in the activation of 
term labor. 
Raises Raises 
Maymon et al 2000, 
Locksmith et al 2001, 
Weiss 2007, 
Vincent et al 2015 
Timp-1 Fetal membranes Regulates the concentration of matrix metalloproteinases. Raises Reduces 
Vadillo-Ortega et al 
1996, 





Pro- and anti-inflammatory 
role. Down-regulation of 
expression of pro-inflammatory 
cytokines. 
Raises Reduces Lee SY et al 2011, Romero et al 2014 
MPO Neutrophils 
Produces oxidative radicals, 
activates endothelial cells to 
produce cytokines, 
extra- and intracellular 
hypochlorus acid production. 
Raises ? Odobasic 2016 
Elastase Neutrophils 
Hydrolyzes connective tissue 
components outside cells, such as 
elastin and collagen types I-IV. 
Plays a role in the pathogenesis of 
membrane rupture. 
Raises Raises 
Kidokoro et al 2006, 




decidua, placental  
syncytiotrophoblast 
Prevents uterine infection. 
Regulation of inflammation. 
Inhibitory effect on neutrophil 
elastase. 
Chemotactic activity on 
neutrophils and macrophages.  
Raises Reduces 
King et al 2007a, 
King et al 2007b, 
Stock 2007 
CRP Fetal liver Not fully clarified Raises ? Malek et al 2006 





 Table 6. Test performances of selected amniotic fluid biomarkers for infection and inflammation. 
 
Study Year N 
GA at  
testing 
Membrane 
status Outcome Biomarkers cut-off Sensit Specif PPV NPV 
Romero et al 1990 168 na Intact MIAC Glucose 14 mg/dL 86.9 91.7 62.5 97.8 











Odibo et al 1999 88 22-36 Intact HCA Glucose 15 mg/dL** 28.3 94.6 88.2 47.9 






































































Buhimschi et al 2007 169 17 - 36.1 
Intact 
































































Tambor et al 2012 72 24 - 34+5 PPROM 
MIAC  
and HCA Cathelicidin 4 ng/mL 47.0 95.0 na na 
Cobo et al 2012 47 22 - 33+6 PPROM MIAC IL-6  na 69.0 81.0 47.0 91.0 
Romero et al 2014 100 22.3-33.4 
Intact 








70.0 na na 
Romero et al 2014 100 22.3-33.4 
Intact 








62.1 na na 
Chaemsaithong 
 et al 2016 136 27-32.4 Intact 
MIAC 
HCA or FS 
FS 













*17mg/dL = 0.94 mmol/L 
**15mg/dl = 0.84 mmol/L 
GA, gestational age; Sensit, sensitivity; Specif, specificity; PPV, positive predictive value; NPV, negative predictive value; 
PPROM, preterm prelabor rupture of the membranes; LD, lactate dehydrogenase, MMP-8, matrix metalloproteinase-8, IL-6, 
interleukin-6; HNE, neutrophil elastase; MMP-9, matrix metalloproteinase-9; HCA, histologic chorioamnionitis; IAI, intra-







AF-glucose determination is a standard method for detecting IAI. AF-glucose levels show a negative 
correlation with AF inflammatory biomarkers, for example with LD (Garry et al. 1996). At the time of IAI, 
the pentose phosphate pathway of microbes fed by glucose is activated, leading to decreased 
concentrations of AF-glucose (Prince et al. 2016). AF-glucose concentrations are associated in high-risk 
pregnancies with maternal serum glucose concentrations (Rinala et al. 2009).  
 
The family of matrix metalloproteinases (MMPs), consisting of 23 zinc- and calcium-dependent peptidases, 
represents genetically distinct but structurally related proteases with a potent ability to degrade almost all 
extracellular matrix components and modify immune responses by modulating cytokines and chemokines 
(Sorsa et al. 2006, Van Lint, Libert 2006, Alfakry et al. 2016). This action is necessary for recruitment of 
inflammatory cells to the inflammatory site (Alfakry et al. 2016). The main components of such extracellular 
matrix in the amnion-chorion are collagens (Vadillo-Ortega et al. 1996). MMPs, which can activate each 
other and form immunological cascades together with their counterparts (Alfakry et al. 2016), are 
produced by activated decidual neutrophils of maternal origin (Gomez-Lopez et al. 2014), and these 
degranulate MMPs and other proteolytic enzymes, e.g. neutrophil elastase (NE), as a response to 
inflammation and neoplasms (Weiss et al. 2007).  
Structural similarities of MMPs indicate that they probably come from the same ancestor (Sorsa et al. 
2006). They are subdivided based on their structure into collagenases (MMP-1, -8, -13), gelatinases (MMP-
2, -9), stromelysins (MMP-3, -10, -11), matrilysins (MMP-7, -26), membrane-type MMPs (MMP-14, -15-17, -
24, -25), and others (MMP-12, -19-21, -23, -27, -28). 
During uncomplicated pregnancy MMP-1, -2, -3, -7, and -9 exist in AF and in the membranes, although 
during pregnancy until labor the amount of MMP-9 is low (Weiss et al. 2007).  
 
MMP-8 (collagenase -2, neutrophil collagenase) is the most impressive initiator of destruction of the major 
collagen (collagen type-1) of the fetal membranes, the one providing their strength (Maymon et al. 2000b, 
Sorsa et al. 2011). MMP-8 is synthesized and stored mainly in polymorphonuclear neutrophils (PMNs) in 
secondary granules as a latent enzyme (Alfakry et al. 2016), and upon stimulation is released as a mature 
MMP-8. Several MMP-8 isoforms exist (Hanemaaijer et al. 1997). Notably, during inflammation, MMP-8 is 
expressed in other cell types as well, such as monocytes/macrophages, plasma cells, and epithelial cells and 
it participates in leucocyte recruitment.  
MMP-8 levels are increased in preterm labor, in PPROM, and in IAI (Maymon et al. 2001a, 2001b), and 
MMP-8 participates in the fetal inflammatory response to IAI (Park et al. 2009, Lee et al. 2015) and has 
shown an association with neonatal morbidity with a cut-off of 30 ng/mL (Maymon et al. 2001a).  
 
MMP-2 belongs to the gelatinases. It is expressed in endothelial cells and trophoblasts and is not produced 
by neutrophils (Seval et al. 2004). It is activated from proMMP-2 that exists on the cell surface (Sorsa et al. 
2006, Vincent et al. 2015). At labor, MMP-2 is the major MMP in the decidua (Weiss et al. 2007) and 
responsible for its gelatinolytic activity. MMP-2, together with MMP-9, is responsible for the mechanism of 
membrane rupture (Maymon et al. 2000a), although MMP-2 is present in the fetal membranes throughout 
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the pregnancy; its concentration increases soon before oncoming labor (Vincent et al. 2015). In AF, MMP-2 
levels are higher in midtrimester than at term, prior to labor (Maymon et al. 2000a). The effect of PPROM 
on MMP-2 levels has been contradictory among studies: Fortunato et al. (1999) reported an increase in 
MMP-2 levels, whereas Maymon et al. (2000a) reported a decrease in the PPROM setting. Levels of MMP-2 
remain unchanged in preterm labor with intact membranes (Fortunato et al. 1999).  
 
MMP-9 (gelatinase B) is produced mainly in neutrophils, but also in macrophages, eosinophils, and smooth 
muscle cells, as well as in endothelial and epithelial cells. It is stored in the secondary granules of 
neutrophils as a latent enzyme, as is MMP-8 (Alfakry et al. 2016). Unlike MMP-8, MMP-9 is released as an 
inactive form and is activated locally.  
MMP-9 levels are increased during inflammation and neoplasm, and its expression can be induced by 
MMP-7 and by various cytokines (Sorsa et al. 2006, Alfakry et al. 2016). MMP-9 is not evident in fetal 
membranes without infection or labor (Weiss et al. 2007), but in AF its level remains almost constant during 
the pregnancy prior to labor (Maymon et al. 2000a).  
 
Tissue inhibitor of metalloproteinases -1 (TIMP-1) is a glycosylated protein that can inhibit all MMPs 
except MMP-19 and membrane-type MMPs (Sorsa et al. 2006). Four TIMPs exist, each having its own 
targets (Visse, Nagase 2003). TIMPs are expressed in normal conditions as well as in inflammatory stages, 
and are produced mainly by endothelial cells, smooth muscle cells, monocytes, and macrophages (Alfakry 
et al. 2016); but in neutrophils it is scarce. Findings on TIMP-1 levels in cases of PPROM are contradictory. 
Fortunato reported them to be slightly increased, whereas the latter two studies reported them to be 
decreased in PPROM, reflecting the imbalance in MMP-8/TIMP-1 leading to rupture of the membranes 
(Vadillo-Ortega et al. 1996, Fortunato et al. 1999, Weiss et al. 2007).  
Cathelicidin is an antimicrobial peptide participating in the innate host defence system (Ramanathan et al. 
2002). The only cathelicidin in humans is hCAP-18/LL-37 (Tambor et al. 2012). Its active form is expressed 
mainly by neutrophils and epithelial cells including amnion epithelium (Tambor et al. 2012, Wang et al. 
2014), but in a smaller amount it appears also in lymphocytes, monocytes, and mast cells (Williams et al. 
2006). Cathelicidin has potent antimicrobial and anti-inflammatory activity (Wang et al. 2014), and also the 
capability to stimulate cytokines like IL-6 (Lim et al. 2015). It is actively passaged transplacentally during late 
pregnancy and delivery, but what is not fully clarified is whether AF cathelicidin is of maternal or fetal origin 
or both (Yoshio et al. 2003, Wang et al. 2014). Levels of cathelicidin are enhanced by stress such as normal 
labor (Mandic Havelka et al. 2010, Park et al. 2011).  
 
Interleukin-6 (IL-6) is a pro-inflammatory cytokine (Burns et al. 2015) and also a potent activator of 
neutrophils and acute phase responses. It has the capacity to modulate the immune response from innate 
immunity to adaptive immunity (Buhimschi et al. 2009, Lee et al. 2011). One major function of IL-6 is 
recruitment of neutrophils to the inflammation site (McGeough et al. 2012). Its concentration increases 




Elafin belongs to a family of antileukoproteinases (Stock et al. 2007) and is synthesized and secreted locally 
upon stimulation by cytokines (Williams et al. 2006). It is produced by neutrophils, chorion trophoblasts, 
decidua, and epithelial cells (Williams et al. 2006, King et al. 2007a, 2007b), for example in amnion 
epithelium (Stock et al. 2007). Among these sites, the chorion plays a massive role in elafin production 
(Stock et al. 2007). Elafin is a peptide with natural antimicrobial and anti-inflammatory properties as well as 
the capacity to modify immune responses (King et al. 2007b); it is an antiprotease of HNE (King et al. 
2007b), protecting tissues from damage mediated by HNE (Williams et al. 2006). Its expression in amnion 
epithelium cells is reduced in cases of PPROM (King et al. 2007b).  
 
Neutrophil elastase (HNE), a serine protease which fragments proteins ingested by leukocytes, is expressed 
and stored in the primary granules of activated neutrophils. It participates in a host response against 
bacteria (Alfakry et al. 2016), and can degrade many extracellular matrix components (Kidokoro et al. 2006) 
through MMP cascade activation (Alfakry et al. 2016). Elastase can affect the activation of MMPs and 
cytokines and the inactivation of TIMP-1 (Alfakry et al. 2016). In PPROM pregnancies, its expression is 
increased (Helmig et al. 2002). 
 
Myeloperoxidase (MPO) is a cationic heme protein, which is stored in PMN, released mainly by neutrophils 
and monocytes, and upregulated with inflammation (Kindzelskii et al. 2006, Leppilahti et al. 2014, Alfakry et 
al. 2016). It has two kinds of properties: first, it degrades foreign particles oxidatively, and second, it 
suppresses the inflammatory reaction (Klebanoff et al. 2013). An important feature of MPO is its ability to 
generate oxidants like hypochlorus acid (HOCl), which can activate latent MMPs (Saari et al. 1992, Alfakry 
et al. 2016) and inactivate TIMP oxidatively. Another important feature is its capability of regulating 
neutrophil immigration to the site of inflammation (Alfakry et al. 2016). In sum: MPO can create an 
environment favorable for necrosis and for abscess formation (Klebanoff et al. 2013). Furthermore, MPO 
also has antimicrobial properties, and HOCl has microbicidal properties (Kindzelskii et al. 2006, Klebanoff et 
al. 2013). 
 
CRP, an acute-phase reactant, is produced in the liver upon stimuli of pro-inflammatory cytokines (Genc, 
Ford 2010). AF CRP, of fetal origin (Malek et al. 2006), is a large-sized protein, incapable of crossing the 
placental barrier (Gutteberg et al. 1986).  
 
Microbial invasion of the amniotic cavity 
 
Microbial invasion of the amniotic cavity is determined as a positive microbial finding in the AF, detected 
either by 16S rRNA (PCR), bacterial culture, or Gram stain.  
PCR is a molecular microbiologic technique used since 1983 (Mullis, Faloona 1987), and is based on cycles 
of heating and cooling DNA strips in order to melt and replicate DNA enzymatically. Primers, i.e. specific 
DNA fragments which are complementary to the target, will attach to the DNA strand. A cycle will be 
repeated many times. As the process continues, the generated DNA can serve as a template so the amount 
of DNA can be amplified.  
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PCR has allowed identification of more microbes than with cultivation techniques, and the rate of identified 
MIAC cases has increased 30 to 50% (DiGiulio 2012). PCR recognizes not only live microbes but also the 
footprints of pre-existing, non-viable microbes (DiGiulio 2012).  PCR has also improved the detection of 
Ureaplasma, the most common microbe in AF (DiGiulio 2012). Furthermore, the method is quicker than the 
traditional cultivation technique.  
Cultivation is a traditional method for identifying microbes. Because bacterial culture and PCR do not 
always identify the same microbes, the spectrum of microbes found has widened when both methods are 
used simultaneously (DiGiulio et al. 2010). With common cultivation techniques, Candida species can also 
be recognized. A negative culture result does not necessarily mean the absence of bacteria, but the 
impossibility of cultivating such a bacteria, because only 1% of bacteria are cultivable (Romero et al. 2006, 
DiGiulio 2012).  
Gram stain is a rapid and cheap method for identifying MIAC. Its basis is to stain bacteria according to their 
cell structure. Gram-positive cells stain as purple and gram-negative as red. For a positive culture, Gram 
stain has a sensitivity of 60% and specificity of 99% (Romero et al. 1993b).  
 
Vaginally obtained samples 
 
After rupture of the fetal membranes, AF can be visible in the vagina during a speculum examination. In 
such situations, AC can be difficult or impossible to perform due the resulting oligohydramnion or 
anhydramnion. Investigation has therefore focused on the possibility of using vaginally obtained AF 
samples. 
Increased AF-LD concentration, measured from vaginally obtained AF samples with a cut-off value of 1000 
IU/L, has shown an association with MIAC detected by AC (Magloire et al. 2006b). Another study linked an 
AF-LD cut-off of 25 IU/L to HCA (Hendsch et al. 2001).  
One study showed that vaginally obtained AF-Gluc correlates with glucose concentrations retrieved by 
transabdominal AC and is also associated with MIAC (Buhimschi et al. 2006). Vaginally obtained AF-Gluc 
concentrations less than 0.28 mmol/L predicted IAI (determined as low glucose concentration at AC with 
MIAC) in that same study with sensitivity of 47% and specificity of 100%. 
IL-6 has failed to prove useful in vaginally obtained AF samples (Hendsch et al. 2001). However, a recent 
publication demonstrated its value in the diagnosis of MIAC, intra-amniotic inflammation, and IAI. It 
showed a strong correlation with IL-6 levels in AC samples, rs=0.68, p<0.0001 (Musilova et al. 2016). 
Recently, a new transcervical device has been introduced for AF collection after PPROM (Lee et al. 2015). 
This may help in sampling and in avoiding contamination with vaginal discharge. 
Cervicovaginal fluid samples containing various biomarkers are under extensive study to discover the most 
suitable predictive biomarker for MIAC and inflammation. The most popular biomarker under investigation 
has been IL-6. An association of IL-6 and tumor necrosis factor –α (TNF- α) with fetal inflammatory response 
syndrome (FIRS) (determined as increased IL-6 in cord plasma) and funisitis has been reported in samples 
obtained by squeezing vaginal discharge from sanitary napkins (Kunze et al. 2016). IL-6 and IL-8 in cervical 
fluid samples have also shown an association with intra-amniotic infection /inflammation (Holst et al. 2005, 
Park et al. 2013b) and with MIAC and HCA (Kacerovsky et al. 2015a). Moreover, cervicovaginal fluid IL-6 has 
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also shown an association with MIAC in pregnancies with intact membranes (Combs et al. 2015), as has 
vaginal fluid IL-6 in pregnancies with PPROM (Kacerovsky et al. 2015b). One study combined gestational age 
with IL-6 values and found this to be best the predictor for IAI in PPROM pregnancies (Ryu et al. 2013). 
A rapid point-of care test, based on IL-6 levels in vaginal secretions and developed for PPROM situations, 
has a positive predictive value (PPV) of 50% and a negative predictive value (NPV) of 97.4%, suggesting use 
of this test in inflammation exclusion. 
 
Maternal serum samples 
 
In pregnancies complicated with IAI, maternal serum IL-6 levels are increased (Dulay et al. 2015). Pregnancy 
itself does not raise IL-6 levels in uneventful pregnancy if levels are compared to those at the non-pregnant 
stage (Anderson et al. 2013). In fact, many conditions cause IL-6 overexpression. For instance, IL-6 is the 
only cytokine associated with MIAC in maternal serum samples in pregnancies with intact membranes, 
whereas in PPROM pregnancies, IL-18, monocyte chemoattractant protein -1, and IL-1β levels are slightly 
increased with MIAC. Moreover, the maternal serum response to MIAC is visible only at <32 weeks of 
gestation (Cobo et al. 2013). Other maternal serum markers have been investigated as well, but have not 




IL-6, CRP, and procalcitonin tests of maternal urine to learn whether IAI can be diagnosed from urine 
samples have failed. Unfortunately, urine is not a useful biological product in the diagnosis of IAI with these 
biomarkers (Dulay et al. 2015). 
Risk-based methods have also been developed. One such involves gestational age, cervical length, and 





HCA diagnosis is based on placental histopathologic examination after delivery. Several systems staging 
HCA severity exist. Currently, the most popular is the system of Redline (Redline et al. 2003, 2005). The 
definition and staging of acute HCA and funisitis according to the Amniotic Fluid Infection Nosology 
Committee of the Perinatal Section of the Society of Pediatric Pathology (Redline et al. 2003) are: 
 “Stage 1 (acute subchorionitis/acute chorionitis): presence of neutrophils in the subchorionic zone 
or in the extraplacental membranes´ chorionic trophoblast layer. 
 Stage 2 (acute chorioamnionitis): more than a few neutrophils accumulated in the chorionic plate 
and connective tissues or in the amniotic membrane. 
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 Stage 3 (necrotizing chorioamnionitis): robust neutrophilic infiltration with visible degenerating 
neutrophils, thickened amniotic basement membrane, and focal epithelial necrosis of the amniotic 
membranes.” 
Salafia and Blanc have also created classification systems (Blanc 1981, Salafia et al. 1989).  
 
Maternal clinical symptoms and signs and infectious markers do not reliably predict HCA (Edwards 2005, 
Erdemir et al. 2013). However, maternal fever >38ºC, spontaneous onset of labor, and duration of labor 
>12 h are the best predictive factors among the symptoms and clinical signs (Roberts et al. 2012). Maternal 
CRP before delivery has been associated with funisitis (Lee et al. 2012), but according to one review and a 
recent study it has no relevant association with HCA in PPROM pregnancies (van de Laar et al.  2009, Stepan 
et al. 2016). On the other hand, in such pregnancies, HCA has been associated with oligohydramnios on 
admission, elevated maternal CRP level just before delivery, but not at admission, small gestational age at 
PPROM, and latency after PPROM (Wu et al. 2009, Xie et al. 2015), though controversial results also exist 
concerning the latency time (Kim et al. 2016).  
Maternal serum IL-6 and IL-8 levels are increased in patients with HCA, but concerning IL-6 this can be seen 
only in PPROM pregnancies, and in term pregnancies with or without PROM (Murtha et al. 1996, Saji et al. 




Reports state that in AF microbes can form biofilms (Romero et al. 2007). If such a biofilm exists near the 
internal os of the cervix, it can be visible during ultrasound as sludge (Figure 5) (Espinoza et al. 2005, 
Kusanovic et al. 2007, Kim et al. 2015a). Sludge occurs in 23% of preterm pregnancies with intact 
membranes, but in only 1% in term labors (Espinoza et al. 2005).  
 
Figure 5. Sludge at ultrasound examination, 










Ultrasound approaches to predicting fetal systemic inflammatory response (SIRS) do exist. For example, 
possible changes in the fetal spleen can be evaluated in response to HCA, and small size of the fetal thymus 
has been linked to IAI, HCA, and funisitis (Musilova et al. 2013, Mastrolia et al. 2016). Unfortunately, low 
specificity makes thymus size unusable as a non-invasive tool in the diagnosis of subclinical 
chorioamnionitis (Musilova et al. 2013). However, pulsation of the splenic vein can serve as such a tool, and 
it is linked to HCA and funisitis in PPROM pregnancies by the same investigators (Musilova et al. 2012). 
Incorporation of these ultrasound markers is not easily available, however, since they require expensive 
equipment and high expertise in fetal ultrasound. 
A recent review on the utility of fetal ultrasonography in prediction of SIRS has summarized all relevant 
studies, with the conclusion that, currently, only invasive methods can be reliably useful for gathering 
information on fetal well-being in women with threatening preterm delivery (Mastrolia et al. 2016). The 
same authors, however, encourage the use of ultrasound in such pregnancies, to help identify those who 
may require invasive procedures. 
 
Prevention and management 
 
Prophylaxis 
The major risk factor for developing clinical chorioamnionitis is expectant management after PPROM (Tita, 
Andrews 2010). Chorioamnionitis occurs in up to 70% of those developing contractions in such a situation, 
though antibiotic prophylaxis reduces the incidence (Tita, Andrews 2010). In a systematic Cochrane review 
by Kenyon et al. (2013), prophylactic antibiotics had no effect on the rates of respiratory distress syndrome 
(RDS), intraventricular hemorrhage (IVH), necrotizing enterocolitis (NEC), or perinatal death. Prophylactic 
antibiotics were, however, associated with prolongation of pregnancy after PPROM, reduced numbers with 
neonatal infection, reduced need for surfactant, and reduced consumption of oxygen (Kenyon et al. 2013). 
The recommendation of induction of labor after 34 weeks of gestation in cases of PPROM (Tita, Andrews 
2010) is still followed in modern obstetric practice worldwide, but recent studies have shown it 
unnecessary in the absence of intra-amniotic inflammation or infection (Kacerovsky et al. 2014, Morris et 
al. 2016). Two recently conducted randomized controlled trials have shown that in pregnancies 
complicated with PPROM between 34+0 and 36+6 weeks of gestation, induction of labor does not improve 
pregnancy outcomes more than does expectant management (van der Ham et al. 2012). Moreover, 
expectant management improves neonatal outcome without any increase in early-onset neonatal sepsis 
(EONS) (Morris et al. 2016). AC was not incorporated into the management of the patients in those 2014 
and 2016 trials. 
In pregnancies with intact membranes and the threat of preterm labor, antibiotic prophylaxis is not 
recommended in the absence of signs and symptoms of chorioamnionitis because of its possible further 
harm to the neonate (Flenady et al. 2013).  
The antibiotic regimens and duration of prophylaxis vary among studies. In the 2010 review by Cousens et 
al. the most common prophylactic antibiotics were ampicillin and erythromycin. Clarithromycin has shown 
a better protective effect on progression of funisitis (Kwak et al. 2013). Co-amoxiclav, conversely, is 




Treatment with broad-spectrum antibiotics immediately after diagnosis of chorioamnionitis reduces the 
rate of EONS cases (Fishman, Gelber 2012). Concerning maternal and neonatal complications associated 
with chorioamnionitis, according to a recent Cochrane review, no suggestions for antimicrobial regimens, 
for continuation of antibiotic use during the postpartum period, or for the length of antibiotic treatment 
are possible, due to limited evidence (Chapman et al. 2014).  
The antibiotics chosen should be effective against the most common microbes causing neonatal sepsis: 
Group B Streptococcus and E.coli. With cesarean section, anaerobic coverage, for example with 
metronidazole, is the recommendation (Fishman, Gelber 2012). Antibiotic specimens vary among hospitals. 
In the Cochrane database, antibiotics for trials were ampicillin, ampicillin/sulbactam, gentamicin, 
clindamycin, and cefotetan (Chapman et al. 2014). No clear consensus exists as to whether antibiotic 
treatment for a mother with MIAC can eradicate microbes from the amniotic cavity and chorioamniotic 
space (Redline 2004, Gomez et al. 2007, Kim et al. 2015a, Lee et al. 2015). Ceftriaxone, clindamycin, and 
erythromycin have shown no ability to eradicate IAI (Gomez et al. 2007). However, eradication rates are 
better with ceftriaxone, clarithromycin, and metronidazole (Lee et al. 2015). Evidence of successful 
eradication of Ureaplasma exists in a primate model, but for humans, multiple doses of azithromycin 
allowing accumulation in AF may eradicate Ureaplasma (Acosta et al. 2014). Macrolides have a limited 
mean transplacental transfer, only 2.6 to 4.3%, thus affecting eradication results (Heikkinen et al. 2000). Of 
the macrolides, clarithromycin has the best mean transplacental transfer, of 6.1% (Witt et al. 2003).  
Antipyretics can be administered for maternal fever (Higgins et al. 2016).  
In cases of maternal chorioamnionitis, delivery should be completed. Any prolonged time-interval between 
diagnosis and delivery causes an increased risk for maternal sepsis (Johnson et al. 2014). Cesarean section 
should be performed only for obstetrical reasons, not only because of chorioamnionitis (Fishman, Gelber 
2012). In pregnancies <33 weeks, administration of antenatal corticosteroids has been safe without 
negative effects on chorioamnionitis progression (Fishman, Gelber 2012). 
 
Health consequences of chorioamnionitis for the mother 
 
The main adverse outcome of clinical chorioamnionitis is increased risk for preterm delivery (Tita 2010). 
Other consequences to the mother during pregnancy and delivery include labor dystocia and cesarean 
section. Postpartum problems include increased blood loss, pelvic or uterine infection, uterine atony, and 
sepsis / septic shock (Tita, Andrews 2010, Fishman, Gelber 2012, Chapman et al. 2014).  
 
Health consequences of chorioamnionitis for the fetus and newborn 
 
Chorioamnionitis plays a key role in neonatal morbidity and mortality (Hitti et al. 2001, Yoon et al. 2001, 
Garcia-Munoz Rodrigo et al. 2014, Kacerovsky et al. 2014, Liu et al. 2014, Roescher et al. 2014, Kim et al. 
2015a, Xie et al. 2015). Following clear symptoms of chorioamnionitis, prevention of adverse neonatal 
outcomes is difficult or impossible (Yoon et al. 2001, Kim et al. 2015b). Furthermore, intra-amniotic 
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inflammation causes similar adverse neonatal outcomes whether or not MIAC is present (Shim et al. 2004, 
Combs et al. 2014, Romero et al. 2014c). In fact, severity of inflammation is the variable correlating best 
with neonatal outcome (Combs et al. 2014, Lu et al. 2016). Notably, in PPROM pregnancies between 34 and 
37 weeks of gestation in the absence of clinical chorioamnionitis, expectant management does not cause 
an increased rate of EONS (Vijgen et al. 2014, Morris et al. 2016, Ofman et al. 2016), but it does so in very 
low birth-weight infants (Klinger et al. 2009). Both risk for RDS and need for mechanical-ventilator support 
instead rise if labor is induced immediately (van der Ham et al. 2012, Morris et al. 2016). The risk for RDS 
and IVH in pregnancies of less than 34 weeks’ of gestation can be reduced with administration of antenatal 
corticosteroids; this seems to be a safe procedure even if the mother has chorioamnionitis (Amiya et al. 
2016). 
The key element is whether a fetus develops FIRS, which is associated with short-term and long-term 
neonatal morbidity and mortality even after adjustment for gestational age (Mastrolia et al. 2016). FIRS is 
determined as elevation of circulating cytokines (IL-6) in the fetal circulation capable of causing damage to 
multiple fetal organs and threatening onset of preterm delivery (Redline 2004, Romero et al. 2014d). Fetal 
organs affected by FIRS include the skin, heart, lungs, kidneys, brain, intestine, thymus, adrenal gland, and 
blood cells (Gotsch et al. 2007). The fetal response is more severe in preterm pregnancies with intact 
membranes than in those with PPROM (Park et al. 2013d); FIRS is, however, more common in PPROM 
pregnancies (50%) compared to pregnancies with intact membranes (39%) (Mastrolia et al. 2016). 
Histologic indicators of FIRS include funisitis and vasculitis in the chorion, and funisitis is, by itself, 
associated with adverse neonatal outcomes (Romero et al. 2006).  
If bacteria invade the uterine cavity, half the fetuses will be colonized by maternal microbes (Romano-
Keeler, Weitkamp 2015), since microbes can reach the fetus by various routes, for example through the 
skin, ear, or gastrointestinal tract (Maxwell et al. 2006). Fetuses exposed to both MIAC and HCA in PPROM 
pregnancies develop more severe FIRS than do those fetuses exposed to either MIAC or HCA (Kacerovsky et 
al. 2014) (Table 7). 
 
Table 7. Association of chorioamnionitis with neonatal outcome.  
 
Study Year Setting 
Inclusion 
criteria n Outcome 
Soraisham 2013 HCA vs 
neurodevelopmental outcome 
<29 GW 384 CP ↑ 
Suppiej 2009 HCA vs  
neurodevelopmental outcome 
<32 GW 104 speech delay, hearing loss↑ 
Rovira 2011 HCA vs  neurodevelopmental outcome 
<32 GW or 
 <1500 g 177 
HCA: any grade motor abnormalities ↑ 
Funicitis: CP, moderate to severe  
    neurological  disability ↑ 
CC: disability of any grade, 
   speech abnormalities ↑ 
Polam 2005 HCA vs  neurodevelopmental outcome 22-29GW 177 
IVH, ROP ↑ 
CP ↔ 
Mental and psychomotor index ↔ 
Horvath 2012 HCA vs cerebral palsy <1500 g 141 CP ↑ 
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Lu 2016 HCA and FIRS vs brain injury  
in PPROM pregnancies 
<34 GW 103 IVH gr 3-4 , PVL↑ 
Gisslen 2016 HCA 32-36 GW 477 mechanical ventilation↑ 
Park 2015 HCA vs RDS 24.5-34 GW 378 mild to moderate HCA: RDS↓ 
Zanardo 2009 HCA  
vs respiratory outcome 
<33 GW 287 Chronic lung disease ↑ Protection from RDS ↔ 
Plakkal 2009 HCA vs BPD <29 GW 529 BPD ↓ 
Huetz 2016 HCA 
 vs neonatal outcome 
24 - 33+6 626 Early onset sepsis ↑ 
CP, death ↔ 
Lee 2013 HCA vs adverse neonatal outcome in PPROM pregnancies 34+0-36+6 244 
Sepsis↑ 
RDS, ventilator, 5 min Apg score ↔ 
Hendson 2011 HCA vs adverse neonatal outcome 
<32 GW and  
<1250 g 628 
Early sepsis, BPD, ROP, mental delay ↑ 
RDS, CP ↔ 
After adjustment: any adverse outcome ↔ 
Xie 2015 
Reprospective study; HCA vs 




Pneumonia, sepsis, BPD, mortality,  
abnormal us findings ↑ 
Lee JY 2016 CC and HCA vs NEC <32 GW 354 NEC ↔ 
Pappas 2014 
HCA and CC  vs  
neurodevelopmental outcome  
at 18-22 months of age 
<27 GW 2390 
sepsis, IVH ↑ 
after adjustment for GA 
cognitive impairment ↑ if HCA and CC 
Musilova 2015 
Infection, inflammation, MIAC 
or negative in PPROM 
pregnancies 
24+0-36+6 GW 166 No difference between the groups 
Aziz 2009 CC vs no chorioamnionitis in  PPROM pregnancies 24-34 GW 1153 
low Apgar scores at 5 min of age ↑ 
RDS, NEC, IVH, pneumonia ↑ 
Ballard 2016 Chorioamnionitis vs BPD <32 GW 1687 BPD ↔ 
Alexander 1999 Retrospective study;  CC in term pregnancies 
neonatal 
weight 





Ylijoki 2016 Chorioamnionitis vs neurological outcome at 2 and 5 years of age 
very low birth-
weight 




197 CC: neurodevelopmental problems ↔ HCA: cognitive outcome at 5 year of age↓ 
Mu 2007 Chorioamnionitis vs  
neonatal outcome 
<1500 g 95 BPD ↑ Mental and psychomotor index ↔ 
Wu 2000 Meta-analysis; CC and HCA vs CP preterm and  full term 
26  
studies 
Preterm: both HCA and CC CP, cPVL↑ 
Term:CC CP↑ 
Shatrov 2010 Meta-analysis; chorioamnionitis vs CP 




HCA: CP ↑ 
CC: CP↑ 
ACS, antenatal corticosteroids; BPD, broncopulmonary dysplasia;  CC clinical chorioamnionitis; CP, cerebral palsy; cPVL, cystic 
periventricular leucomalacia; FIRS, fetal inflammatory response syndrome; GA, gestational age; HCA, histologic chorioamnionitis; 
IVH, intraventricular haemorrhage; MIAC, microbial invasion of the amniotic cavity; NEC, necrotizing enterocolitis; PPROM, preterm 





Clinical chorioamnionitis raises risk for EONS OR 5.84 (95% CI 3.03-11.25) and for grade 3-4 IVH OR 1.60 
(95% CI 1.16-2.21) when adjusted for birth weight and gestational age (Soraisham et al. 2009). In preterm 
pregnancies, risk for neonatal morbidity and mortality is the higher the smaller are gestational age and 
birth weight (Fishman, Gelber 2012). The rate of meningitis is 3%, NEC 4.5%, pneumonia 10-21%, sepsis 7-
28%, IVH 22-24%, and RDS 62-63% in preterm pregnancies (Fishman, Gelber 2012). HCA and FIRS are more 
common in fetal survivors, suggesting that progression of fetal response may promote early survival (Lahra, 
Jeffery 2004). Although some studies question the profound impact of HCA on long-term 
neurodevelopmental outcome (Ylijoki et al. 2016), the majority of studies demonstrate this association 
(Rovira et al. 2011, Fishman, Gelber 2012); this was evident particularly in the increased incidence of CP 

























Aims of the study 
 
The present study was carried out to evaluate whether vaginally obtained AF biomarkers could prove 
clinically valuable in the diagnosis of HCA, and to find the association of selected AF biomarkers obtained by 
AC in women with suspected IAI with MIAC, HCA, and neonatal outcome. 
 
The detailed aims were to study: 
1. Whether vaginally obtained AF can serve for IAI diagnostics based on AF-LD and AF-Glucose 
measurements and to evaluate their association with HCA. 
 
2. The association of AF-LD and AF-Glucose in AC samples with MIAC and HCA and to determine cut-
off values for clinical purposes. 
 
3. The association of the novel AF biomarker cathelicidin and AF-MMP-8 in AC samples with MIAC, 
and to determine cut-off values for clinical purposes. 
 
4. The difference in selected novel biomarkers between IAI-suspected cases and controls without IAI 




















A description of the women enrolled in the studies (I-IV) is presented in Table 8.  
Table 8. Patients and methods in Studies I-IV. 










IAI  GW 22+0-h36+6 
PPROM and no 
PPROM 
patients with 
suspected IAI GW 
22+0-h35+0 
patients with intact 
membranes 
 and IAI suspicion GW 
22+0-32+0 









LD and glucose  
vs HCA 
 
LD and glucose vs  
MIAC and HCA 
 
MMP-8 and  
cathelicidin vs MIAC 
 
new biomarkers in cases 
and controls; within cases 





AC samples of AF AC samples of AF AC samples of AF 
Outcome HCA MIAC and HCA MIAC MIAC and adverse neonatal outcome 
Number of 
patients 53 70 54 27 
  
3 from Study I 
67 new patients 
3 from Study I 
27 from Study II 
(includes 3 from 
Study I) 
27 new patients 
8 from Study II  
19 from Study III  
(includes 8 from Study II) 
8 new patients 
Controls  -  -  - 46 
PPROM= preterm prelabor rupture of membranes; GW, gestational weeks; LD= lactate dehydrogenase; HCA= histologic 
chorioamnionitis; MIAC, microbial invasion of the amniotic cavity; AC, amniocentesis; AF, amniotic fluid 
 
 
A total of 232 women with suspected IAI or PPROM were recruited as cases and 80 women as controls in 
the period between March 2012 and October 2015. AC was performed in 139 cases with suspected IAI and 
in the 80 controls. Vaginal AF samples were from 96 women with PPROM. After exclusions, the final study 
group comprised 155 women and the control group 46 women, for whom AC was performed in 105 cases 





Figure 6. Enrolled women and exclusion criteria. 
 
All studies were conducted at the University Hospital of Helsinki, Finland, Department of Obstetrics and 
Gynecology. PPROM was diagnosed by clinical examination or by a positive vaginal point-of-care test 
(ActimProm®, Medix Biochemica, Espoo, Finland). Determination of gestational age was based on the first-
trimester (12+0 - 13+6 weeks of gestation) ultrasound screening. IAI suspicion was evoked by at least one of 
the following criteria of chorioamnionitis: uterine tenderness, maternal fever, fetal tachycardia, infectious 
discharge from uterine cervix, increased maternal plasma CRP >10 mg/L, total maternal plasma WBC count 
> 20 x 109/L, or sludge visible at ultrasound examination (Table 9).  
 
Table 9. Signs and symptoms of intra-amniotic infection (IAI) in IAI 
suspected cases. 
  PPROM No PPROM p-value 
n 100 55 
Uterine contractions n (%) 55 (55) 40 (73) 0.03 
Uterine tenderness n (%) 11 (11) 25 (45) <0.001 
Maternal fever >38°C n (%) 5 (5) 2 (4) 1.0 
Malodorous discharge n (%) 13 (13) 11 (20) 0.25 
Maternal CRP >10 mg/L n (%) 71 (71) 50 (91) 0.004 
Maternal WBC count >20 x 109 /L n (%) 18 (18) 5 (9) 0.129 
Sludge n (%) 13 (13) 11 (20) 0.25 





Prophylactic intravenous antibiotics (azithromycin 500 mg daily and cefuroxime 1.5 g three times daily) for 
three consecutive days after PPROM and two subsequent doses of intramuscular betamethasone for fetal 
lung maturation (12 mg twice 24 h apart) were administered to all women with PPROM. Antenatal 
corticosteroids, but not routine antibiotics, were administered also to women with intact fetal membranes 
and imminent preterm labor before 35 weeks of gestation. Tocolysis was administered to women by 
decision of the obstetrician in charge if no signs of clinical chorioamnionitis were present. If possible, the 
women with PPROM were managed expectantly until 34 weeks of gestation, when labor was induced or 
caesarean section was performed.  Immediate delivery was performed earlier if symptoms and signs 
consistent with clinical chorioamnionitis occurred or at any sign of maternal and fetal compromise. The 
results of AF-LD, AF-Gluc, AF PCR, and AF microbial culture were available to obstetricians during the study 
period. If AF-LD was less than 419 IU/L and AF-Gluc more than 0.7 mmol/L without MIAC at AC, pregnancy 




The study population comprised 96 pregnant women with PPROM. This prospective study was conducted 
between March 2012 and March 2015. Gestational age on admission was between the 22+0 and 36+6 weeks. 
All had vaginally collected AF samples on admission and then repeated samples every third day if possible if 
undelivered. The placental histopathologic result after delivery was recorded. The main outcome 
measurement was association of AF-LD and AF-Gluc with HCA in vaginally collected AF samples. We 
excluded the 19 women without placental histopathology and eight lacking an AF-LD value, those 12 with 
their last examination–to-delivery-interval beyond 72 hours, the one with gestational age less than 22 
weeks at examination, and three with multiple pregnancies. Thus, the final study group comprised 53 
women. 
No microbial analysis of vaginally obtained AF samples took place. Classical criteria were those that 




The study population comprised 104 women with singleton pregnancies between 22+0 and 36+6 weeks of 
gestation with or without PPROM. The study was conducted between March 2012 and March 2015. AC was 
performed for any suspected IAI. The 34 women with an AC-to-delivery interval of over 7 days were 
excluded. The final study group comprised 70 women. The main outcome measures were the association of 
AF-LD and AF-Gluc with MIAC and HCA. 
The following laboratory tests were performed: AF-LD and AF-Gluc concentrations, AF PCR and AF microbial 
culture. Microbial results were available for 62 cases. The results of bacterial culture were available for 46 






The study population comprised 57 women with singleton pregnancies between 22+0 and 35+0 weeks of 
gestation and suspected IAI with or without PPROM.  The study was conducted between June 2012 and 
March 2015. Exclusion criteria for recruitment were multiple gestations, pregnancies with structural fetal 
anomaly, proven or suspected fetal aneuploidy. Those pregnancies lacking any microbial analysis were 
excluded from the final analysis, which comprised 54 women. The main outcome measures were the 
association of AF-MMP-8 and AF-cathelicidin with MIAC and with HCA. 
The following laboratory tests were performed: AF-MMP-8 and AF-cathelicidin concentrations, AF microbial 
culture, and AF PCR. 
Controls were 32 healthy women with singleton pregnancy between 15+0 and 36+6 weeks of gestation and 
uneventful pregnancy outcome who underwent measurements of AF-MMP-8 and AF-cathelicidin 
concentrations. Indications for AC in these pregnancies were karyotyping in 24 or evaluation of fetal lung 




This cohort included 73 women with a singleton pregnancy and intact fetal membranes. The study group 
comprised 27 women with suspected IAI who were recruited in the study group and 80 women with AC 
performed for other indication than IAI who were recruited as controls. We excluded the 24 controls with 
gestational age less than 17 weeks, eight with diabetes mellitus type I, and two with twin pregnancies. The 
final study group, comprising 27 cases and 46 controls, was gathered between June 2013 and October 
2015. Membranes were considered intact in the absence of any clinical signs of membrane rupture.  
The cases underwent AC between 22+0 and 32+0 weeks of gestation and the controls between 17+0 and 37+5 
weeks of gestation. Indications for AC in controls were mid-trimester chromosomal analysis in 28, 
determination of fetal lung maturity in one, and evaluation of fetal chronic hypoxia by erythropoietin 
measurement in 17. Of controls, five had pre-eclampsia, and four had insulin-treated gestational diabetes. 
Fetal growth restriction (fetal growth below -2 standard deviation) was noticeable in four pregnancies. 
Exclusion criteria were fetal structural anomaly, proven or suspected fetal aneuploidy, and diabetes type I. 
The selected biomarkers were AF-MMP-8, AF-MMP-9, AF-MPO, AF-IL-6, AF-HNE, AF-Elafin, AF-MMP-2, AF-
TIMP-1, AF- MMP-8/TIMP-1 molar ratio, and AF-CRP. AF microbial culture and AF PCR, AF-LD, and AF-Gluc 
concentrations were also determined. 
The main outcome measures were the difference in selected AF biomarkers between cases and controls, 









Collection of the clinical data 
 
Data for the study population such as maternal age, body mass index (kg/m2), parity, smoking, gestational 
diabetes, delivery mode, and neonatal outcome came from the hospital database and laboratory results 
from analyses performed for clinical purposes, not for the study.   
 
Samples and assays 
 
Vaginally obtained amniotic fluid samples (I) 
 
AF samples were obtained either during a speculum examination for 19 with a syringe in cases of AF 
pooling in the vagina, or by self-collection by 34 in a favorable situation with a plastic cup if no AF was 
visible during clinical examination. AF samples were collected on admission and afterwards on every third 
day if possible. 
AF-LD and AF-Gluc were analyzed in HUSLAB by the Modular P System (Roche Diagnostics, Penzberg, 
Germany) and according to International Federation of Clinical Chemistry (IFCC) recommendations. AF-LD 
measurement was by a quantitative assay for total enzymatic activity of lactate dehydrogenase (including 
the activity of all LD-isoenzymes, LD1-LD5), according to IFCC recommendations. This method was 
generated for automated clinical chemistry analyzers of Roche. The intra-assay coefficient of variation (CV) 
for AF-LD was < 2.3%, and the detection limit was 5 IU/L (I, II). The detection limit of AF-Gluc during the 
study period was 0.50 mmol/L (I, II). In the low concentration levels (under 4 mmol/L), the intra-assay CV 
was 4.7%, while at higher concentration levels (up to 42 mmol/L), the intra-assay CV was 1.9%. Values of 
AF-Gluc < 0.5 mmol/L were recorded as 0 in statistics. 
Amniotic fluid samples by amniocentesis (II-IV) 
 
AF samples were obtained by transabdominal AC under ultrasound guidance and an aseptic technique from 
women with suspected IAI and from healthy controls undergoing AC for chromosomal analysis or 
evaluation of fetal lung maturity.  
AF-LD and AF-Gluc were analyzed in HUSLAB by the methods described under “Vaginally obtained amniotic 
fluid samples”.  
AF samples were divided into aliquots, frozen, and stored at -20 °C until analyzed in a single laboratory 






Immunoenzymometric assay (IEMA) of MMP-8 (III, IV)  
 
MMP-8 IEMA is a quantitative enzyme immunoassay for the determination of human MMP-8. This 
sandwich assay uses two monoclonal antibodies against human MMP-8 (Medix Biochemica, Espoo, 
Finland). By that method, microplate wells were coated with one monoclonal antibody against MMP-8. To 
run the assay, 80 μl of Assay Buffer and 20 μl of standards, controls and samples were added to the 
microplate wells. Next, the plate was left for incubation for one hour at room temperature on a shaker. At 
that time, MMP-8 was bound to the microplate wells. Thereafter, unbound substances were washed out. In 
the next step, 100 μl of the enzyme conjugate was added to each well. The plate was then incubated again, 
100 μl of enzyme substrate was added, and the plate was shaken again for 15 minutes. The reaction was 
stopped by addition of 50 μl of an acidic stopping solution. The absorbance of the solutions in the wells was 
measured at 414 nm with a microplate reader (Multiskan, Thermo Fisher Scientific, Vantaa, Finland). The 
concentrations of controls and samples were obtained from the standard curve created.  
Other biomarkers (III, IV) 
 
Commercial enzyme-linked immunosorbent assays (ELISA) allowed analysis of other biomarkers according 
to the manufacturer´s instructions: AF-cathelicidin  [Human LL-37 [HK321] ELISA kit, Hycult biotech, PB 
Uden, The Netherlands], AF-CRP [Human C-Reactive Protein (CRP) ELISA kit, R&D Systems, Minneapolis, 
MN, USA], AF-Elafin [Human Trappin-2 (Elafin) ELISA kit, RayBiotech, Norcross, GA, USA], AF-HNE 
[Polymorphonuclear (Human PMN Elastase) Sandwich ELISA kit, eBioscience, Vienna, Austria], AF-IL-6 
[Interleukin-6 (IL-6) ELISA kit, R&D Systems], AF-MMP-2 [Matrix Metalloproteinase 2 (MMP-2) ELISA kit, 
R&D Systems], AF-MMP-9 [Matrix Metalloproteinase 9 (MMP-9) ELISA kit, R&D Systems], AF-MPO 
[Myeloperoxidase (MPO) ELISA kit, Immunodiagnostik AG, Bensheim, Hesse, Germany], and AF-TIMP-1 
[Tissue inhibitor of metalloproteinases 1 (TIMP-1) ELISA kit, GE Healthcare, Buckinghamshire, UK]. 
Microbiological analyses (II-IV) 
 
MIAC was determined as either positive AF microbial culture or positive microbial PCR. Cultivation of AF 
samples for aerobic and anaerobic bacteria was performed on chocolate blood agar in 5% CO2 and on 
Fastidious Anaerobe Agar, enriched with a thioglycolate broth, in anaerobic conditions at 35±1 °C. The 
cultivation took seven days, and the specimens were inspected after one, two, and seven days. Detection of 
common Candida spp. and Mycoplasma hominis, but not Ureaplasma spp. was achievable.  
For molecular microbiologic technique analyses, a minimum of 500 μL of AF was subjected to ceramic bead-
beating cell lysis (Precellys®24 tissue homogenizer, Bertin Technologies, Montigny-le-Bretonneux, France) 
and then to a magnetic-bead-based DNA extraction method (NucliSENS kit with easyMAG automatic nucleic 
acid purification platform, bioMérieux, Marcy l'Etoile, France) according to the manufacturer´s instructions. 
The extracted DNA was extended in duplicates by PCR using the following primers: 5´- TTG GAG AGT TTG 
ATC MTG GCT C -3´ (forward) and 5´- GTA TTA CCG CGG CTG CTG -3´ (reverse). Inhibition control in the PCR 
reaction was based on DNA of λ-phage. Gel-electrophoresis served for verification of a positive PCR 
product, 5 μl of the PCR product was sequenced in a core facility, and the sequence acquired was compared 
to a NCBI BLAST sequence database (www.ncbi.nlm.nih.gov/blast). The Ripseq mixed analysis tool 




Placental samples (I, II) 
 
A pathologist examined all placentas histopathologically, one with experience in perinatal pathology. Gross 
examination of the placenta, fetal membranes, and umbilical cord preceded accompanied recording of 
placental weight. Sampling sites were cord insertion, placental margin, chorionic plate, cord, and 
extraplacental membranes. Sections of tissue blocks were stained by standard hematoxylin and eosin 
techniques. HCA was defined as a visible diffuse infiltration of polymorphonuclear leukocytes - which are 
not normally present in the chorioamniotic membranes - in any sample associated with edema and 
congestion of the vessels. Inflammation of the umbilical cord (funisitis) was separately recorded, but not 
analyzed as an independent variable in this study. HCA was categorized as present or absent. 
Maternal and neonatal blood samples (I, IV) 
 
Maternal and neonatal plasma CRP was measured by an immunoturbidometric method ( Modular System, 
Roche Diagnostics). Maternal and neonatal blood samples were obtained according to standard clinical 




Comparisons of categorical variables of baseline clinical data were analyzed by Chi-square test and by the 
Fisher exact test if the number of cases was under five. Data with continuous variables were analyzed by T-
test when the data followed a normal distribution (I). Data with continuous variables not following a 
normal distribution were analyzed by Mann-Whitney U-test (I-IV). Comparisons of continuous variables in 
three groups were calculated by Kruskall-Wallis test (unpublished data). Non-parametric correlations were 
calculated by Spearman´s rank correlation coefficient test (III-IV). Bivariate correlation analysis served to 
test the association of biomarkers with neonatal outcome (IV). AF biomarker concentration values were 
regressed on gestational age at sampling and on gestational age at delivery, and the residual served as a 
dependent variable for computing adjusted p-values (I-IV). Receiver operating characteristic (ROC) curves 
were derived to evaluate the diagnostic performances of AF biomarkers in prediction of MIAC or HCA and 
area under the curve (AUC), with 95% confidence interval (95% CI) determined (I, II, III). The sensitivity, 
specificity, PPV, and NPV were calculated (I, II, III). All tests were two-sided and processed by the Microsoft 
Statistical Package for the Social Sciences (SPSS) for Windows (Chicago, IL, USA), version 21.0 (I), and 









Each patient signed a written informed consent. The study was approved by the Helsinki University Hospital 
Ethics Committee for gynecology and obstetrics, pediatrics, and psychiatry (75/13/03/03/2013). Patients 
were advised that the risk for any undesirable consequences requiring immediate delivery after AC (fetal 
injury, placental abruption, large fetal-vessel laceration, or PPROM in cases of intact membranes) is 
approximately 0.7% (Stark et al. 2000) and that the data obtained by analyzing samples might provide more 























Of all the women, 87 (43%) were primiparous, and 49 had a body mass index (BMI) >30 (BMI missing for 3) 
and were considered obese. All AC samples in cases were obtained between 22+0 and 36+5 weeks of 
gestation. Selected variables of demographic data of the study population are in Table 10.  
 




Vaginally obtained amniotic fluid samples (I) 
 
HCA occurred in 37 (70%) women. Mean (SD) gestational age at PPROM was 28.5 (±3.9) weeks of gestation. 
PPROM occurred earlier in women with HCA than in those without HCA (p=0.04). The median 
concentrations of AF-LD were higher in patients with HCA than in those without HCA (Table 11), but this 
difference disappeared when the concentrations were adjusted for gestational age at sampling 
(unpublished data). AF-Gluc concentrations between women with or without HCA did not differ.  
Table 11. Median concentrations of AF-LD and AF-Gluc in women with and without histologic 








LD IU/L median (range) 1400 (128-23000) 784.5 (135-3542) 0.005 0.59 
Gluc mmol/L median (range) 0.0 (0.0-3.5) 0.65 (0.0-3.0) 0.20 0.41 
LD, lactate dehydrogenase; Gluc, Glucose 
*Adjusted for gestational age at sampling; unpublished data 
 
The cut-off value of AF-LD based on the ROC curve was 1029 IU/L (AUC 0.74; 95% CI 0.61-0.88) for HCA. AF-
LD concentration 1029 IU/L predicted HCA with a sensitivity of 65%, specificity 69%, PPV 83%, and NPV 
46%. Positive likelihood ratio (LR+) was 2.1 for HCA. A total of 30 (57%) women had AF-Gluc concentration 
below 0.5 mmol/L. When AF-LD and AF-Gluc were used in a combination with cut-off values for AF-LD 1029 
IU/L and for AF-Gluc 0.5 mmol/L, they showed a performance for HCA with a sensitivity of 53%, specificity 
81%, PPV 86%, and NPV 43%.  
The examination-to delivery interval for vaginally collected amniotic fluid samples before delivery was less 
than 72 hours.  Furthermore, nine women had three repeatedly obtained AF-LD samples during a 10-day 
period. Eight (89%) of those women had HCA. AF-LD showed marked fluctuation in repeatedly obtained 
samples (Figure 7). No difference in AF-LD (p=0.15) or in AF-Gluc (p=0.42) concentrations occurred based 
on sampling method, self-sampling or speculum samples.  
 
Figure 7. Fluctuation of AF-LD in vaginally 
collected samples in nine cases during a 
10-day period. Sample 3 (the last) was 
obtained <72 h before delivery. All except 
case number 9 had HCA.  
AF, amniotic fluid; LD, lactate dehydrogenase; 
HCA, histologic chorioamnionitis. 
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Amniotic fluid samples obtained with amniocentesis (II-IV) 
 
Association of biomarkers with MIAC (II, III, IV) 
 
MIAC was detectable in 30 (48%) women in Study II, in 18 (33%) women in Study III, and in 7 (26%) IAI-
suspected cases in Study IV. All biomarkers except AF-MMP-2 and AF-CRP were associated with MIAC, and 
the association with MIAC concerning biomarkers of Studies III and IV appeared also when biomarker 
concentrations were adjusted by gestational age at sampling (unpublished data concerning Studies II and 
III). AF-cathelicidin and AF-MMP-8 were associated with MIAC both in pregnancies with intact membranes 
and in pregnancies with PPROM. When biomarker concentrations were adjusted by gestational age at AC, 
AF-cathelicidin, AF-MMP-8, AF-MMP-9, AF-MPO, AF-IL-6, AF-HNE, AF-Elafin, AF-TIMP-1, and AF-MMP-
8/TIMP-1 molar ratio were associated with MIAC (Table 12). 
 
 
Table 12. Association of biomarkers studied with MIAC in Studies II to IV. 




n 30 32   
LD IU/L 1514.5 (91-9698) 694 (62-3882) 0.012 0.317 
Gluc mmol/L 0.05 (0.0-3.4) 1.1 (0.0-6.0) 0.002 0.063 
Study III 
n 18 36   
MMP-8 ng/mL 4907.5 (45-13292) 13.5 (3-6591) <0.001 <0.001 
cathelicidin ng/mL 25.6 (3.2-42.9) 1.3 (0.5-28.1) <0.001 <0.001 
Study IV 
n 7 20 
MMP-8 ng/mL 3019 (69-5431) 7.5 (3-2372) <0.001 <0.001 
MMP-9 ng/mL 2981 (84-9678) 3.4 (0.7-730) <0.001 <0.001 
MPO ng/mL 4866 (267-79095) 299 (75.6-55185) 0.002 0.001 
IL-6 ng/mL 94.9 (5.6-540) 0.6 (0.03-1021) <0.001 0.002 
HNE ng/mL 11280 (315-16380) 12.3 (2.8-9862) <0.001 <0.001 
Elafin ng/mL 1533 (58-10491) 191 (7-4642) 0.031 0.016 
MMP-2 ng/mL 311 (266-938) 231.5 (153-696) 0.081 0.055 
TIMP-1 ng/mL 3958 (1456-9752) 1178 (633-9317) 0.001 0.001 
MMP-8 /TIMP-1 molar ratio 0.167 (0.011-0.973) 0.004 (0.001-0.155) <0.001 <0.001 
CRP ng/mL 133 (23-1783) 42.5 (5-985) 0.092 0.092 
median (range)  
MIAC, microbial invasion of the amniotic cavity 
MMP-8, matrix metalloproteinase -8; MMP-9, matrix metalloproteinase -9; MPO, myeloperoxidase; IL-6, 
interleukin -6; HNE, neutrophil elastase; MMP-2, matrix metalloproteinase -2; TIMP-1, Tissue inhibitor of 




The most optimal cut-off values based on the ROC curve for MIAC was determined for both AF-LD and AF-
Glucose (Study II), and for AF-MMP-8 and AF-cathelicidin (Study III). The performances and accuracies of 
these biomarkers in relation to MIAC are in Table 13. Concomitant use of AF-LD together with AF-Gluc 
(Study II) or AF-MMP-8 with AF-cathelicidin (Study III) did not improve the accuracies. 
 
Table 13. Cut-off values based on ROC curve and accuracies of amniotic fluid biomarkers in 
amniocentesis samples. 
Biomarker n Outcome Prevalence % Cut-off AUC (95% CI) Sensitivity Specificity PPV NPV LR+ 
LD IU/L 62 MIAC  48 429 0.69 (0.55-0.82)  87 38 57 75 1.4 
Glucose mmol/L 62 MIAC  48 0.7 0.72 (0.59-0.85) 67 66 65 66 2.0 
LD and Glucose 62 MIAC  48 67 66 65 66 2.0 
MMP-8 ng/mL 54 MIAC  33 41.5 0.90 (0.82-0.98) 100 69 62 100 3.2 
cathelicidin ng/mL 54 MIAC  33 11.6 0.90 (0.82-0.98) 89 81 70 94 4.7 
MMP-8 and cathelicidin 54 MIAC  33 89 81 70 94 4.7 
LD, lactate dehydrogenase; MMP-8, matrix metalloproteinase-8; MIAC, microbial invasion of the amniotic cavity; HCA, 
histologic chorioamnionitis 
The most optimal cut-off values are based on ROC curve. 
  
 
MIAC in pregnancies with PPROM and intact membranes (II, III)  
 
Of all 97 women in Studies II to III, PPROM occurred in 50 (52%). In Study II, PPROM occurred in 41 (59%) 
cases and in Study III in 25 (46%), but 16 of the women served in both studies. Microbial results were 
available in 90 women of Studies II and III, and MIAC occurred in a total of 35 (39%) of those; 13 women 
with microbial result served in both studies. MIAC occurred equally often in women with PPROM and in 
those with intact fetal membranes (Figure 8).  
 
Figure 8. The frequency of MIAC in pregnancies 
with or without PPROM. In the No PPROM 4/43 
were missing microbial analysis results and in 







Microbial findings (II-IV) 
 
Table 14. Microbiologic findings in amniocentesis samples, Studies II to IV. 
 
Case no PPROM +/- Microbe in PCR Microbe in culture 
PCR+ and Culture+ 
1  - Streptococcus viridans Streptococcus viridans 
2  - Streptococcus pneumoniae Streptococcus pneumoniae 
3  - Fusobacterium nucleatum Candida 
4  + Hemophilus influenzae Hemophilus influenzae 
5  + Peptostreptococcus anaerobius Peptostreptococcus anaerobius 
6  - Peptostreptococcus anaerobius Peptostreptococcus anaerobius 
7  - Streptococcus agalactiae Streptococcus agalactiae 
8  + 
Ureaplasma urealyticum / parvum 
Bacteroides ureolyticus 
Candida 
9  + Ureaplasma urealyticum / parvum Candida 
PCR+ and Culture - 
10  + Ureaplasma urealyticum / parvum Neg 
11  + Ureaplasma urealyticum / parvum Neg 
12  - Ureaplasma urealyticum / parvum Neg 
13  - Ureaplasma urealyticum / parvum Neg 
14  + Ureaplasma urealyticum / parvum Neg 
15  - Ureaplasma urealyticum / parvum Neg 
16  + Ureaplasma urealyticum / parvum Neg 
17  - Ureaplasma urealyticum / parvum Neg 
18  - Ureaplasma urealyticum / parvum Neg 
19  - Bacteroides ureolyticus Neg 
20  + Ureaplasma urealyticum / parvum Neg 
21  + Fusobacterium nucleatum Neg 
22  + Mycoplasma hominis Neg 
23  + Ureaplasma urealyticum / parvum Neg 
24  - Bacteroides ureolyticus Neg 
25  + Streptococcus viridans NA 
26  + Ureaplasma urealyticum / parvum Neg 
27  - Mycoplasma hominis Neg 




PCR- and Culture+ 
29  - Neg Coagulase negative Staphylococcus 
30  + Neg Gardnerella vaginalis 
31  - Neg Candida 
32  + Neg Gardnerella vaginalis 
33  + Neg Candida 
34  - Neg Gardnerella vaginalis 
35  + Neg Candida 
PPROM, preterm prelabor rupture of the membranes; PCR, polymerase chain reaction, implemented for 16Sr 





Microbial results were available for 97 cases, of which 35 (36%) had MIAC (Table 14). The most common 
microorganism was Ureaplasma species (n=14) followed by Candida species (n=6). Of MIAC cases, 4 (11%) 
were polymicrobial. Only by PCR were 19 (54%) cases detectable and 7 (20%) only by bacterial culture 




Culture result was available in 74 (missing n=23) and PCR result in 92 women (missing n=5). 
Figure 9. Distribution of microbiology results according to method.  
 
 
Infection and inflammation (III) 
 
Infection and inflammation were more common at a lower gestational age when either AF-MMP-8 or AF-
cathelicidin was a marker of inflammation and infection was determined as an increased value of 
inflammation marker in the presence of MIAC (Figures 10 and 11). Membrane status had no an effect on 
infection rate. Rate of colonization was affected neither by gestational age nor by membrane status.  
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Figure 10. Number of patients 
at amniocentesis with 
infection (microbial invasion 
of the amniotic cavity+ 
(MIAC+), MMP-8 >41.5 
ng/mL), inflammation (MIAC-, 
MMP-8 >41.5 ng/mL), 
colonization (MIAC+, MMP-8 
<41.5 ng/mL), and negative 
(MIAC-, MMP-8 <41.5 ng/mL) 
in AF by MMP-8. None had 
colonization (MIAC+, MMP-8 









Figure 11. Number of 
patients at amniocentesis 
with infection (microbial 
invasion of the amniotic 
cavity+ (MIAC+), cathelicidin 
>11.6 ng/mL), inflammation 
(MIAC-, cathelicidin >11.6 
ng/mL), colonization (MIAC+, 
cathelicidin <11.6 ng/mL), 
and negative (MIAC-, 
cathelicidin <11.6 ng/mL) in 
AF by cathelicidin. GW, 










Association of biomarkers with HCA (II, and unpublished data) 
 
In Study II, HCA occurred in 53 (76%) of the women, and funisitis in 19 (36%). The most optimal cut-off 
values based on the ROC curve for HCA were for AF-LD and AF-Glucose. The performances and accuracies 
of these biomarkers in relation to HCA are in Table 15. 
 
Table 15. Cut-offs of AF-LD and AF-Glucose for the prediction of HCA. 




off AUC (95% CI) Sensitivity Specificity PPV NPV LR+ 
LD IU/L 70 HCA 76 % 429 0.76 (0.62-0.90)  83 65 88 55 2.4 
Glucose mmol/L 70 HCA 76 % 0.7 0.70 (0.58-0.83) 56 82 91 38 3.1 
AF, amniotic fluid; LD, lactate dehydrogenase; HCA, histologic chorioamnionitis 
 
 
PPROM was diagnosed in 41 (59%) women. No difference appeared either in rate of HCA between 
pregnancies with PPROM and with intact membranes (Figure 12), or in rate of symptoms and signs of IAI 
except for uterine tenderness, which occurred more frequently in pregnancies with intact membranes.  
 
 
Figure 12. Frequency of HCA-














Association of MMP-8 with HCA with or without MIAC (unpublished data) 
The study population comprised 34 women, of whom 18 (53%) had PPROM. MIAC occurred in 18 (53%). In 
comparing AF-MMP-8 concentrations between groups with both HCA and MIAC (n=18), HCA without MIAC 
(n=8), and with neither HCA nor MIAC (n=8), AF-MMP-8 had the highest median concentration in cases with 
both HCA and MIAC [4219.5 ng/mL (45-13292)], followed by those with  HCA but no MIAC [1550.5 ng/mL 
(90-6145)], while the lowest concentrations were in those with neither HCA nor MIAC [53.5 ng/mL (3-
6591); p=0.021 between the three groups] (Myntti et al., unpublished data).  
 
Neonatal outcome (IV) 
 
Neonatal short-term outcome was evaluated of 27 neonates, of whom, 11 (41%) were born before 32 
weeks of gestation. All nine cases of adverse neonatal outcome occurred among neonates born before 29 
weeks of gestation. Six (67%) of them were born from a pregnancy complicated with MIAC. EONS occurred 
in two (7%) neonates. Table 16 demonstrates that inflammation and MIAC are more common in neonates 
born <32 weeks of gestation than in those born ≥ 32 weeks. 
 
Table 16. Inflammation and MIAC by gestational age at delivery. 
  <32+0 GW >32 GW p-value 
n 11 16 
GW at AC 29 (27-31) 30 (22-31) 0.8 
AF Inflammation, n (%) 8 (73%) 1 (6%) 0.031 
AF MIAC, n (%) 6 (55%) 1 (6%) 0.10 
median (range) 
Inflammation, MMP-8 >41.5ng/mL 
MIAC, microbial invasion of the amniotic cavity; GW, gestational weeks; 














Preterm delivery is the major cause of neonatal death and an important causative factor of neonatal 
morbidity (Slattery, Morrison 2002, Rovira et al. 2011). Intra-amniotic infection or inflammation should be 
diagnosed appropriately for optimal timing of delivery, steroid administration, and magnesium 
neuroprophylaxis, as well as for the decisions regarding tocolysis or antibiotics therapy. However, regarding 
massive cytokine release in AF as a consequence of MIAC or endogenous mediators, preterm birth or 
PPROM in many cases can no longer be prevented (Kim et al. 2015a). Unfortunately, no accurate method 
exists to diagnose IAI with reliability noninvasively (Buhimschi et al. 2013, Dulay et al. 2015), which we also 
noticed in our study of vaginally obtained amniotic fluid samples.  
Romero et al. (2016a) have reported on increased levels of pyrogenic cytokines in maternal plasma in term 
pregnancies with symptoms of clinical chorioamnionitis despite intra-amniotic infection or inflammation. 
These results reflect the fact that pyrogenic cytokines are produced separately from IAI or clinical 
chorioamnionitis, which fact makes fever an unreliable sign for chorioamnionitis. In our studies, fever was 
rarely present despite the more frequent presence of IAI. Furthermore, these results of the Romero group 
confirm that symptoms and signs of clinical chorioamnionitis are only nonsensitive and nonspecific 
subjective findings. 
 
Vaginally obtained amniotic fluid samples (I) 
 
We demonstrated that in vaginally obtained AF samples, AF-Gluc was useless as a biomarker for HCA 
prediction. The cut-off for AF-Gluc in vaginal samples in the Buhimschi study was 0.28 mmol/L (Buhimschi 
et al. 2006), but during the study period our laboratory could not determine any exact values below 0.5 
mmol/L. Over half of the AF-Gluc results were below our detection limit, without any difference exerted by 
either the presence or the absence of HCA. One reason for this finding may be the difficulty of obtaining AF 
vaginally without contamination by vaginal discharge, leading to possible bias in the analysis of results; 
vaginal discharge and serum have almost identical glucose concentrations (Ehrstrom et al. 2006).  
In our study, AF-LD was associated with histologic chorioamnionitis, although that association disappeared 
with data adjustment by gestational age. Small sample size may affect the results after adjustment. 
Although the PPV was quite high, this marker is insufficiently accurate for use in clinical practice due to 
fluctuation of its concentration in samples repeatedly obtained. Our cut-off value for AF-LD based on the 
ROC curve in relation to HCA was in line with others’ findings, where vaginally obtained AF-LD 
concentration was associated with MIAC determined by AC sample (Magloire et al. 2006b). We found no 
difference between AF-LD and AF-Gluc concentrations in self-sampling and speculum samples, indicating 
that no special device for AF collection vaginally is necessary, at least concerning these biomarkers, 
although Lee et al. (2015) have introduced a new transcervical device for AF collection in order to obtain 
samples uncontaminated with vaginal discharge. Their study, however, reports only the correlation of 




Association of biomarkers with MIAC (II-IV) 
 
The benefits of AF-Gluc and AF-LD determination in IAI diagnostics are these markers’ wide availability, 
rapidity, and low costs. The Romero group in 1990 was first to observe an association between AF-Gluc and 
MIAC with a cut-off of 0.8 mmol/L, which was in line with our study findings, though our method for MIAC 
detection differs from theirs. Although, in several reports, decreased glucose levels are associated with 
MIAC (Romero et al. 1990, Garry et al. 1996, Edwards et al. 2001, Ford, Genc 2011), no such association 
exists with sterile inflammation (Romero et al. 2014). This may be explained by the fact that glucose 
metabolism is not altered in the absence of microbes. Thus, AF-Gluc is not a marker of inflammation, but 
instead, a marker of MIAC. 
AF-LD has also shown an association with MIAC, as first described almost 40 years ago (Bobitt, Ledger 
1978). They had a cut-off level of 400 IU/L, although their samples were collected during delivery. Garry 
was the first, in 1996, to describe an AF-LD cut-off 419 IU/L for MIAC, which was later clinically evaluated by 
other authors (Buhimschi et al. 2007a, 2007b, Dulay et al. 2009). Although the NPV of AF-LD in the Garry 
study was high, its PPV was markedly low (Garry et al. 1996). The results of our research are also in line 
with these, and our cut-off for the presence of MIAC is close to theirs, although the methods of detecting 
MIAC differed. Our association of AF-LD and AF-Gluc with MIAC was lost after adjustment for gestational 
age, which may, at least in part, be explained by our small study population. Moreover, and importantly, 
the earlier studies did not adjust their concentrations of AF-LD and AF-Gluc for gestational age. 
It is of importance that contrary to many earlier studies of AF-LD and AF-Gluc, we used both AF cultures 
and a molecular microbiology technique for the determination of MIAC, which enabled us to find more 
MIAC cases than by AF culture only. 
Interestingly, although our cut-off value for AF-LD in relation to MIAC was almost identical to that 
determined by Garry et al. in 1996, Buhimschi et al. in 2007b, and Dulay et al. in 2009, our cut-off value for 
AF-MMP-8 concentration was set at 41.5 ng/mL, higher than the cut-off chosen in the previous studies 
(Park et al. 2001, Shim et al. 2004, Lee et al. 2007, Park et al. 2013a, Lee et al. 2015a). Importantly, we 
determined MMP-8 concentrations by the IEMA method, whereas they used Amersham ELISA or ELISA by 
R&D Systems (Buhimschi et al. 2007b, Lee et al. 2016). MMP-8 antibodies vary in their affinities to different 
MMP-8 isoforms, which leads to divergence in MMP-8 levels measured. Studies show that due to the 
higher affinity for the active form of MMP-8 of antibodies that they used, as well as in our study, higher 
overall levels of MMP-8 will result (Hanemaaijer et al. 1997, Sorsa et al. 2010, Buduneli et al. 2011). A 
correlation of MMP-8 measurement by immunofluorometric assay (IFMA) with measurement by 
Amersham ELISA exists (Sorsa et al. 2010), as well as a strong correlation between the IEMA and IFMA 
methods of Medix Biochemica (Sorsa T., unpublished data). Taken these into account, comparison of MMP-
8 levels between studies becomes irrelevant if the antibodies used differ.  
MMP-8 has been associated with inflammation (Nien et al. 2006, Lee et al. 2010, Kim et al. 2016), and with 
MIAC in pregnancies with or without PPROM (Maymon et al. 2000b).  A rapid MMP-8 bedside test does 
exist for prediction of intra-amniotic infection and inflammation (Nien et al. 2006) and of MIAC (Lee et al. 
2008). It has been able to predict MIAC and IAI in pregnancies with or without PPROM with high NPV, 
making it a valuable additional tool in ruling out IAI (Nien et al. 2006, Kim et al. 2007, Park et al. 2008, Lee 
et al. 2008). Interestingly, test performances for IAI and MIAC were almost similar in the study of Nien et al. 
(2006) to those of Lee et al. (2008), although in the study of Nien 2006, MIAC was determined only with 
cultivation, and Lee in 2008 also used PCR, as did we. 
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Cathelicidin is expressed mostly in fetal membranes and on other epithelial surfaces –ones that are 
naturally in contact with environmental microbes (Tambor et al. 2012). Because spontaneous delivery is an 
inflammatory process, it is unsurprising that after normal delivery cathelicidin is expressed in myometrium 
(Lim et al. 2015). Cathelicidin is also produced by fetal vernix caseosa (Yoshio et al. 2003), which may be an 
additional source of AF-cathelicidin. The association of AF-cathelicidin with MIAC has been evident in 
PPROM pregnancies (Tambor et al. 2012). However, studies evaluating the association of AF-cathelicidin 
with MIAC in pregnancies with intact membranes were lacking, until we first demonstrated that AF-
cathelicidin levels are higher in MIAC cases despite the membrane status. This observation reflects the 
potential up-regulation of cathelicidin expression in MIAC and furthermore the antimicrobial properties 
concerning the host defence system described earlier (Ramanathan et al. 2002, Yoshio et al. 2003, Lim et al. 
2015).  
It is of importance that both MMP-8 and cathelicidin retained their association with MIAC also when the 
data was adjusted by gestational age at AC. That strengthens the value of these biomarkers in the diagnosis 
of IAI. 
On study showed AF-MMP-2 levels to be decreased in MIAC, but this is visible only in PPROM pregnancies, 
where AF-MMP-2 overall levels are lower than in pregnancies with intact membranes (Maymon et al. 
2000a). In our study of pregnancies with intact membranes, AF-MMP-2 levels did not differ by MIAC. AF-
MMP-9 levels, instead, are increased in the presence of MIAC regardless of fetal membrane status 
(Fortunato et al. 1997, Maymon et al. 2000a) and also during labor (Vadillo-Ortega et al. 1996, Weiss et al.  
2007). We studied only pregnancies with intact membranes, where we could confirm the association of AF-
MMP-9 with MIAC. The difference between the present study and that of Maymon is that we used a 
molecular microbiology technique and cultivation for our determination of MIAC instead of Maymon´s 
cultivation only. 
AF-TIMP-1 has also been linked to MIAC in pregnancies with intact fetal membranes, but unlike ours, only 
bacterial cultivation has been used to determine MIAC (Athayde et al. 1998). 
Several studies have shown the association of AF-IL-6 with MIAC (Greig et al. 1993, Romero et al. 1993a, 
1993b, 1993c, 2014d, Cobo et al. 2013, Dulay et al. 2015), which we could confirm, although our 
determination of MIAC differed from that in studies that used cultivation and Gram stain. When compared 
to AF-Gluc, WBC count, and Gram stain, AF IL-6 has been a superior predictor of MIAC in pregnancies with 
preterm labor or PPROM, though the levels of IL-6 were lower in women with PPROM and IAI than in 
women with intact membranes and IAI (Lee et al. 2011). Our study population was too small to allow 
comparison of the accuracies of various biomarkers, and furthermore, we studied only pregnancies with 
intact membranes. Contrary to earlier results, Cobo et al. (2011) found AF-IL-6 to be only a weak marker for 
inflammation in PPROM pregnancies, though these studies used similar methods for MIAC determination.  
One report states that AF-elafin levels are increased in chorioamnionitis, and AF-HNE levels are increased in 
MIAC regardless of membrane status (Rivero-Marcotegui et al. 1997, Helmig et al. 2002, King et al. 2007a). 
Contrary to our findings, these studies determined MIAC with only cultivation.  We also demonstrated 
increased AF-Elafin and AF-HNE concentrations in pregnancies with MIAC, although we studied only 
preterm pregnancies with intact membranes.  
Studies concerning AF-MPO and AF-CRP regarding IAI are few. Kacerovsky et al. (2013) have reported an 
association of AF-MPO with MIAC and HCA in PPROM pregnancies. We could extend that association also to 
preterm pregnancies with intact fetal membranes.  
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AF-CRP levels have been higher in women with MIAC than in those without MIAC (Dulay et al. 2015), 
although AF-CRP concentrations have not been associated with maternal serum CRP concentrations (Malek 
et al. 2006). The Dulay study, unlike ours, included pregnancies with PPROM and with intact membranes. 
We observed that AF-CRP levels did not differ based on the presence or absence of MIAC. The Dulay group 
determined MIAC by cultivation, Gram stain, and mass-spectrometry score, as we did not. Their sample size 
was larger than ours, which may affect results; however, they published no exact AF-CRP values, but 
observed some overlapping between groups. 
AF-CRP is produced in the fetal liver (Malek et al. 2006), and its concentration is not supposed to rise until 
the fetus is infected and CRP production has begun. Furthermore, as a large protein, CRP probably is 
incapable in a substantial amount of transference through the fetal kidneys into urine and AF, at least no 
longer in later pregnancy, though it has been detectable in fetal urine at the time of genetic AC (Raio et al. 
2003). CRP´s large molecular size makes it also incapable of crossing the placenta, a fact that can explain 
the lack of association between AF and maternal serum CRP levels (Gutteberg et al. 1986).  
Overall, we found that, in MIAC cases, AF biomarkers reflecting neutrophil activation and degranulation 
showed increased concentrations. In contrast, biomarkers that are not neutrophil-based, i.e. AF-MMP-2 
and AF-CRP, did not react with MIAC. 
 
Microbial findings (II-IV) 
 
The rate of MIAC ranges in preterm pregnancies with intact membranes between 8.7% and 34% and in 
PPROM pregnancies between 17% and 57.7% (Review by Kim et al. 2015a). Our rate of MIAC was in line 
with those values. Ureaplasma spp. and Mycoplasma spp. are reported to comprise about half the 
microbes detectable in AF (Keelan et al. 2016). We discovered Ureaplasma spp. in 40% of our MIAC cases. 
Other microbes commonly found in AF in IAI cases are Fusobacterium nucleatum, Mycoplasma hominis, 
Gardnerella vaginalis, Streptococcus species, Bacteroides spp., and Escherichia coli (Mysorekar, Cao 2014, 
Fox, Eichelberger 2015, Kim et al. 2015a). Less frequent is Listeria monocytogens (Buhimschi et al. 2013), 
and a gastrointestinal bacteria Coprobacillus spp., first described by DiGiulio et al. 2010. We observed 
similarities in diversity of AF microbes, as in previous studies. In our study, Candida was the second most 
prevalent microbe, in one-fifth of the cases, though in the literature it has been a markedly less frequent AF 
microbe (DiGiulio et al. 2010). MIAC has been polymicrobial in the recent literature in 11% to 22% of 
pregnancies with PPROM (Musilova et al. 2015, Stepan et al. 2016) and, when PCR or PRC and cultivation 
methods are used in the detection of MIAC, in 9% of pregnancies with intact membranes (Romero et al. 
2014a). Our rate of polymicrobial MIAC was in line with rates in those studies. With only cultivation used, 
one could speculate whether antibiotic treatment before AC had wiped out some MIAC cases, but we 
detected MIAC by PCR, which can also recognize the footprints of pre-existent microbes.  
The role of Ureaplasma spp. as a pathogen of the upper genital tract has been under discussion (Dando et 
al. 2012). Modern microbiologic techniques provide the possibility to detect Ureaplasmas more often than 
with earlier cultivation techniques. Ureaplasma can also be cultivated by special methods, but not in media 
suitable for cultivation of common bacterial species.  We detected Ureaplasma spp. exclusively by reliable 
PCR techniques. Most studies have used no molecular microbiology techniques (Park et al. 2013a, Combs et 
al. 2014), or PCR has been done only for Ureaplasma and Mycoplasma detection (Tambor et al. 2012).  Our 
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AF samples have been analyzed by both broad spectrum 16S rRNA and general bacteria cultivation in order 
to achieve the maximum MIAC detection. Oyarzun et al. 1998 demonstrated an increase in detection rate 
by adding PCR as a diagnostic tool to identify MIAC, observing a threefold increase.   
The theory had been that ascending infection is the most common route for bacteria to reach the amniotic 
cavity and the amnio-choriotic membranes, which leads to higher prevalence of MIAC in pregnancies with 
PPROM than in pregnancies with intact membranes (Soto et al. 2007). However, microbes can indeed pass 
the intact amniotic membranes; therefore MIAC also occurs in pregnancies with intact membranes (Galask 
et al. 1984, Ramos Bde et al. 2015). We observed that the MIAC prevalence was similar in the presence or 
absence of PPROM. This finding differs from ones of Soto et al. 2007, where prevalence of MIAC in PPROM 
pregnancies was over twofold that in pregnancies with intact membranes. One explanation may be the 
differing methods of MIAC detection between studies.  
During recent years, some have demonstrated that the taxonomic profile of the placental microbiome 
resembles that of the oral flora more than of vaginal or fecal flora (Fox, Eichelberger 2015, Vinturache et al. 
2016), which favors hematogenous spread as being one of the crucial pathways of microbial invasion. 
Increased vascular permeability in the gingival tissue during pregnancy concomitantly with periodontal 
disease allows recurrent bacteremia moving towards the placenta (Redline 2012, Madianos et al. 2013, 
Parthiban, Mahendra 2015). We found in AF samples the typical oral microbes Fusobacterium nucleatum 
and Streptococcus viridans. Fusobacterium plays the role of a door-opener for other bacteria species. That 
property may explain the common polymicrobial nature of MIAC (Buhimschi et al. 2013); in our study, 
Fusobacterium was present in half the polymicrobial cases. 
Microbes tend to form biofilms, termed “sludge”. If such is observed, eradication by antibiotics is more 
unlikely than in pregnancies with free-floating AF microbes. Microbes from sludge are also more difficult to 
cultivate (Stewart, Costerton 2001, Donlan, Costerton 2002). This may result in the poor success rate of 
attempts to eradicate IAI, and, at least in part, explain sterile intra-amniotic infection. Overall, because only 
1% of bacteria are cultivable (Romero et al. 2006, DiGiulio 2012), sterile intra-amniotic inflammation may 
reflect only the low sensitivity of detection methods or rapid and effective elimination of microbes by the 
host response (Redline 2012). However, by PCR, microbes eliminated by the host response should be 
recognizable, because PCR does not need living organisms for detection. 
 
Infection and inflammation (III) 
 
The rate of intra-amniotic infection and inflammation is higher at lower gestational ages (Hitti et al. 2001, 
Yoon et al. 2001, Combs et al. 2014), in line with our observations. In addition, our observation that rate of 
AF colonization remained stable across gestational ages support views in other publications (Combs et al. 
2014).  
Evoking of the host defence mechanism is the crucial factor affecting some microbes in some women 
causing chorioamnionitis and sometimes just existing as harmless colonization. The intensity of the 
inflammatory reaction depends on gestational age at the time of the exposure, the virulence factor of a 
microbe, the amount of invading microbes (Kacerovsky et al. 2011, 2012), and the individual properties of 
the host defence system (Genc, Ford 2010). Unfortunately, our analyses did not include quantitative PCR. 
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Controversial reports exist as to the origin of the AF neutrophils: fetal (Sampson et al. 1997, Redline 2012, 
Park et al. 2016) or maternal (Kim et al. 2015a). If they are considered as of maternal origin, they reflect the 
maternal inflammatory response to endogenous mediators or MIAC. The maternal host response is crucial 
in continuation of pregnancy, and on the other hand in limiting the infectious site in the uterus. The uterine 
inflammatory process in its first stage is usually circumscribed, is limited to a certain place until the host 
defence mechanisms fail, yielding to more general infection. In the first stage of infection, inflammatory 
changes are visible only at the site of infection, and only later in a more generalized stage in other places. In 
clinical work, we remain unaware of the current stage of the infection, which clarifies why sampling of 
maternal serum, urine, or of cervical secretions is unreliable in clinical use.   
Antibiotics have anti-inflammatory properties and have the capacity to modify the immune system, in 
addition to their ability to eradicate microbes, and the (Bode et al. 2015). The effect on the immune system 
is transmitted by Toll-like receptors and cytokines, and the spectrum and amplitude of effects on the 
lymphocytes and neutrophils varies among antibiotics (Bode et al. 2014). Doxycycline and macrolides, for 
example azithromycin (Culic et al. 2001), seem effective in immune modulation (Bode et al. 2014). On the 
basis of the available literature (Lee et al. 2016), Ureaplasma as a common pathogen in IAI (Keelan et al. 
2016), and in the preliminary results of our study, we have already modified our antibiotics policy in 
everyday clinical practice by adding azithromycin in addition to the cephalosporines in the management of 
PPROM pregnancies. Macrolides have been included in the antibiotic protocol in another study, as well, 
although they found clarithromycin to be the drug of choice (Lee et al. 2016). One advantage favoring 
azithromycin is its oral administration. 
A new macrolide antibiotic, solithromycin, seems to be valuable in prevention and management of intra-
amniotic infections due to its broad microbial spectrum, high tissue uptake, easy oral administration, anti-
inflammatory properties, and effective placental transfer (Keelan et al. 2016). Antenatal corticosteroids 
also have anti-inflammatory properties, which can be seen in reductions in maternal serum IL-6 and CRP 
levels (Nayeri et al. 2014). Non-steroidal anti-inflammatory drugs do pose a risk for narrowing or closing the 
fetal ductus arteriosus (Bermas 2014), and, more specifically, the use of indomethacin poses a risk for 
adverse neonatal outcome (Hammers et al. 2015); these limit their use in pregnancy. Some reports, 
however, demonstrate that NSAID use during pregnancy does not affect infant survival, neonatal 
complications, or congenital malformations (Nezvalova-Henriksen et al. 2013, Damase-Michel, Hurault-
Delarue 2014). 
In an ovine model, Ireland et al. (2015) demonstrated that intra-amniotic inflammation can be suppressed 
by administration of a cytokine-suppressive anti-inflammatory drug intra-amnially as a single bolus. In 
another animal model, the rate of murine preterm labor and fetal demise was reduced if intra-amniotic 
inflammation induced with lipopolysaccharide was treated with N-acethylcysteine (an agent with both 
antioxidant and anti-inflammatory properties) (Buhimschi et al. 2003, Paintlia et al. 2008). Importantly, a 
recent randomized controlled trial on human newborns exposed to chorioamnionitis shows that treatment 
with N-acethylcysteine is safe (Jenkins et al. 2016). Finally, Buhimschi et al. in 2003 demonstrated in a 
murine model that release of free radicals and a shift in oxidative balance as a consequence of 
inflammation can be normalized with administration of N-acetylcysteine, and the rate of preterm birth 
thereby reduced. Oxidative stress in a human intra-amniotic infection is clearly established, as well (Chafer-
Pericas et al. 2015). However, the applicability of such anti-inflammatory drugs for treatment of intra-
amniotic infection and inflammation in humans needs further investigation of optimal dosage, duration, 
and the route of administration. Moreover, safety of the treatment for the mother should be ensured. 
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Association of biomarkers with histologic chorioamnionitis (II) 
 
AF-Gluc has been associated with HCA with cut-off values of 1.1 mmol/L, though the accuracies in our study 
were reported for a cut-off value of 0.8 mmol/L. AF-Gluc predicted HCA with a sensitivity of 28% and a 
specificity of 95% (Odibo et al. 1999). In another study concerning AF-Gluc levels and HCA in pregnancies 
with intact membranes, different cut-offs for AF-Gluc (0.3 mmol/L- 0.9 mmol/L) were calculated, yielding 
sensitivities of 41% to 55% and specificities of 94% to 100% (Greig et al. 1994, Odibo et al. 1999). AF-LD has 
also shown an association with HCA (Kidokoro et al. 2006). We could confirm the association of AF-Gluc and 
AF-LD with HCA. Our cut-off value for AF-Gluc based on its ROC curve was in line with those in other 
studies. Additionally, we found the same cut-off value to be suitable for both MIAC and HCA. Another 
difference between these studies and ours is the method of MIAC determination, which in those studies 
was based on cultivation.   
Our cut-off value for AF-LD based on the ROC curve was higher than the value in a study of the Kidokoro 
group, 250 IU/L. Its setting differed from ours, since that group, reporting in 2006, accepted women 
between 16 and 35 weeks of gestation eligible for the study. AF-LD has also shown increased levels in cases 
of funisitis (Buhimschi et al. 2007a), which rarely is observed without HCA, because it is considered an 
advanced HCA stage. Their median concentration of AF-LD in funisitis cases was, however, only 414.5 IU/L, 
which was lower than our cut-off level for HCA. 
AF-MMP-8 in our study was higher in women with HCA than in those without, which is in line with previous 
findings (Park et al. 2013a, Kim et al. 2015b). Our AF-MMP-8 levels were increased also in cases with sterile 
HCA, i.e. HCA without MIAC, which have been also demonstrated earlier (Park et al. 2013a), though in that 
study, MIAC was determined with cultivation only, unlike our procedures. We demonstrated additionally 
that AF-MMP-8 concentrations rose more in cases with concomitant HCA and MIAC than in pregnancies 
with one of these alone; this supports use of invasive procedures for diagnosing MIAC, which often leads to 
HCA. 
HCA exists in over half of the cases with MIAC (Romero et al. 2014c, Vajrychova et al. 2016) and in about 
half the cases with sterile inflammation (Romero et al. 2014c), indicating that placental pathology does not 
always correlate with IAI (Pettker et al. 2007). We observed a similar rate of sterile HCA, although we had 
pregnancies both with intact membranes and with PPROM included, but the Romero group studied only 
pregnancies with intact membranes.  
 
Neonatal outcome (IV) 
 
Intra-amniotic inflammation has reportedly caused a more severe fetal response in preterm labor with 
intact membranes than in PPROM pregnancies (Park et al. 2013d). Additionally, the intra-amniotic 
inflammation may cause an adverse neonatal outcome regardless of the presence or absence of MIAC 
(Shim et al. 2004, Combs et al. 2014, Romero et al. 2014c). These findings should warrant a more serious 
view and acute awareness of the complex issue of subclinical chorioamnionitis in pregnancies with or 




The single most important risk factor for neurological disabilities is preterm birth (Salmeen et al. 2014). We 
observed that all neonatal adverse-outcome cases occurred in neonates born at <29 weeks of gestation, 
one-third of them without exposure to MIAC. Preterm birth, per se, even late preterm birth occurring at 
34+0 to 36+6 weeks of gestation, carries a lifelong risk for some neurocognitive disorder, a risk which may 
be slightly alleviated by a high level of education (Heinonen et al. 2015). However, gestational age at 
delivery plays a crucial role in short-term neonatal outcome, one more important than the presence or 
absence of MIAC, sterile inflammation, or IAI (Musilova et al. 2015).  
 
Principal findings on new biomarkers and IAI (IV) 
 
We demonstrated that neutrophil-based proinflammatory cascades are present in AF similar to those in 
periodontal tissues (Alfakry et al. 2016). Concentrations of the neutrophil-based biomarkers AF-MMP-8, AF-
MMP-9, AF-MPO, AF-IL-6, and AF-HNE in IAI and MIAC cases were increased. MMP-8 is a potent protease 
capable of degrading extracellular matrix in many human tissues. The process causing a tooth to detach is 
similar to the process leading to membrane rupture or cervical shortening and opening. IL-6 is a locally, and 
upon-stimuli-secreted, multifunctional cytokine, being an inducer of the neutrophil-based inflammatory 
cascade and causing PMN extravasation at the sites of inflammation (McGeough et al. 2012). Infection and 
inflammation can induce IL-6 and the degranulation of proteases, i.e. MMP-8, MMP-9, HNE, and MPO, from 
activated neutrophils. IL-6, by itself, can act as a PMNs irritating chemoattractant and induce the 
degranulation of MMP-8, MMP-9, and MPO, which form a PMN-derived proteolytic and proinflammatory 
cascade. Furthermore, MPO is an oxidative activator of MMP-8 and MMP-9 as well as an oxidative 
inactivator of TIMP-1 by producing hypochlorus acid (HOCl) (Alfakry et al. 2016). Additionally, HNE and 
MPO, individually or together, can proteolytically and oxidatively inactivate TIMP-1, which leads to 
reduction in the anti-proteolytic shield in the AF. 
HNE can act as a proteolytic activator of MMP-9 but not of MMP-8; thus HNE and MMP-9 form another 
PMN-derived proteolytic cascade, with which elafin associates while being an antiprotease of HNE. That 
role of elafin can explain the increased elafin concentrations in IAI and MIAC cases, though it is only in part 
produced by PMNs and also in epithelial cells. MMP-2 and TIMP-1 are not produced by PMN, but instead by 
resident epithelial cells. TIMP-1 concentrations were also increased in IAI and MIAC cases, thus reflecting 
TIMP-1´s role as a coordinator of MMP-8 concentrations. 
We found that the neutrophilic proinflammatory profile was associated with the general inflammatory 
marker AF-CRP, suggesting activated neutrophils to be the major source of AF-MMP-8, AF-MMP-9, AF-
MPO, and AF-HNE. Our study demonstrates this by the association of these biomarkers with MIAC and IAI. 
These biomarkers retained the association with MIAC also when the data were adjusted for gestational age 
at AC, which strengthens the potential of these biomarkers in the diagnosis of IAI. In this regard, it is 
important that no corresponding associations were detectable in AF-MMP-2 and AF-TIMP-1, which are not 
produced by neutrophils and therefore do not react in neutrophil activation; this observation fortifies the 




Clinical implications and future prospects 
 
Our results confirm the known association of IAI in patients with preterm labor both in PPROM pregnancies 
and in those with intact fetal membranes. Unlike earlier publications, we used cultures together with 
molecular microbiology techniques. According to the preliminary results of MIAC etiology here and in the 
literature, we have modified our prophylactic antibiotic policy and decided to administer azithromycin to all 
patients with PPROM.  
Our forthcoming study regarding comparison of neonatal and maternal outcomes in pregnancies with 
suspected IAI undergoing AC and those without AC is under way. Certainly, the only way to achieve an 
answer concerning the impact of AC on long-term outcome is an adequately powered multicenter 
randomized control trial.  
We suggest that in daily clinical practice, AC should be a routine procedure in IAI diagnosis. The results of 
the currently widely used biomarkers AF-LD and AF-Gluc are available to clinicians, but the delay in 
receiving results of microbial analysis may be several days, resulting in anxiety. We have demonstrated, 
however, that the current biomarkers AF-LD and AF-Gluc are unfortunately not very accurate in MIAC or 
HCA prediction. We were, to our knowledge, the first to study the concomitant use of these biomarkers, so 
that MIAC was detectable by PCR and microbial culture both.   
In vaginally collected AF samples, we demonstrated that AF-LD and AF-Gluc are not useful biomarkers, even 
if used concomitantly. Notably, we also demonstrated that sampling method had no effect on biomarker 
concentrations. Based on these results, vaginal AF sampling has been abandoned thus far in our clinic, until 
we can introduce for vaginal sampling a better biomarker. 
In the present study, we determined cut-off values for the newer biomarkers AF-MMP-8 and AF-
cathelicidin and observed better accuracies than with AF-LD and AF-Gluc. This may help in clinical decision-
making in pregnancies with suspected IAI. Our method to measure MMP-8 concentrations differs from the 
method of earlier IAI studies, as it recognizes better the active form of MMP-8 and yields higher overall 
concentrations of MMP-8. We seem to be the first to demonstrate the association of AF-cathelicidin with 
MIAC in pregnancies with intact membranes.  
A rapid bedside test with the novel markers would be of great value for clinicians, helping ease further 
management decisions and the follow-up of such pregnancies (administration of antenatal corticosteroids, 
magnesium-neuroprophylaxis, and tocolysis) and decisions on optimal delivery timing. Qualitative point-of 
care tests of AF-MMP-8 and AF-IL-6 already exist (Kim et al. 2007, Chaemsaithong et al. 2016a, 2016b). IAI 
exists, however, not just as present or absent; one must bear in mind that intensity of inflammation 
correlates with neonatal outcome, so the magnitude of inflammation should also have an influence on 
clinical decisions. A simple test of just a positive or negative result does not provide information on 
inflammation severity, and therefore we hope to have a rapid test which shows biomarker concentrations. 
Based on our results, in which MIAC was equally common in pregnancies with intact membranes as in 
PPROM pregnancies, we must change our conception of pregnancies with intact membranes and mild 
symptoms as being harmless to being seen instead as potential sites of inflammation. Administration of AC 
as added to the clinical protocol would be of great value in IAI-suspicious cases (Figure 13), at least in 
PPROM pregnancies, because the result of AC can influence our management of such pregnancies.  
Furthermore, AC is justified regardless of gestational week in PPROM pregnancies, because IAI and adverse 






Figure 13. Flowchart of suggested protocol of treatment of IAI-suspected women (By author). IAI, intra-
amniotic infection; GW, gestational weeks; MIAC, microbial invasion of the amniotic cavity; AC, 
amniocentesis; Mg, magnesium. 
 
 
We found that IAI seems to be associated with activation and degranulation of PMN in the same manner as 
in inflammatory conditions in other body systems. Based on that finding, we speculate that neutrophil-
based biomarkers have the best accuracy in the diagnosis of IAI. In the future, neutrophil-based biomarker 
investigation in a larger material and in different panels would be of interest in order to confirm and extend 













Strengths and limitations of the studies 
 
Strengths 
We studied a single tertiary center, which can be assumed to be both a strength and a limitation. Its 
strength: every patient was treated in the same manner, and a single laboratory analyzed our samples, so 
no interobserver variation occurred. Its limitations: the study population was relatively small in every study 
(I-IV), and a multicenter setting could have yield a larger study population. 
We used both PCR and cultivation for determination of MIAC, yielding a higher number of MIAC cases 
identified. 
Limitations 
No multivariate analyses were made, but because the small study population, such analyses would have 
been meaningless. 
Power-analysis is lacking. While studying biomarkers as linear variables, it is difficult to specify a sufficient 
difference between positive and negative results to calculate an adequate number for the study 
population. 
Some patients underwent antibiotic administration before AC, which may lead to some false-negative 
microbial results. PCR, however, recognizes the fingerprints of microbes and requires no living microbes to 
provide a positive result. 
Some patients underwent administration of antenatal corticosteroids before AC, which may lead to some 
misleadingly low biomarker concentrations. 
Racial variabilities in biomarker concentrations were not taken into account. IL-6 concentrations are, 
overall, higher in races of African origin, and there they also show a more robust stress-induced response 
(Christian et al.  2013). Whether the same cut-offs are suitable for all races is unknown. In Finland it is 
impossible to register ethnicity. Our study population consisted mostly of white individuals, which is not the 














On the basis of this study, the following conclusions can be drawn: 
1. In vaginally obtained AF, the lack of association between AF-Gluc and HCA, and an existing 
association, but marked fluctuation in AF-LD makes both of these unreliable for diagnosis of IAI. 
These results indicate that better biomarkers for vaginal AF sampling are essential (I). 
 
2. In AC samples, AF-LD and AF-Glucose are associated with MIAC and HCA, and the same cut-off 
value is suitable for both MIAC and HCA, which do not necessarily coexist. Although the accuracies 
of these biomarkers are not very high, they can serve as a directional, additive diagnostic tool in 
diagnosis of IAI (II). 
 
3. The novel biomarker AF-cathelicidin and the biomarker AF-MMP-8 are associated with MIAC in AC 
samples both in pregnancies with intact membranes and in those with PPROM, reflecting the 
capability of MIAC to upregulate concentrations of cathelicidin. Cut-off values were determined, 
and the cut-off for AF-MMP-8 was higher than in earlier studies (III). 
 
4. AF neutrophil-based biomarkers are associated with MIAC in preterm pregnancies with intact 
membranes, and are capable of separating IAI cases from healthy controls. These findings suggest 
that neutrophil-derived proinflammatory cascades are associated with IAI, as they are with other 
inflammatory conditions in various body systems. The further extension of these results in PPROM 
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